US20030176436A1 - Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof - Google Patents
Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof Download PDFInfo
- Publication number
- US20030176436A1 US20030176436A1 US10/184,855 US18485502A US2003176436A1 US 20030176436 A1 US20030176436 A1 US 20030176436A1 US 18485502 A US18485502 A US 18485502A US 2003176436 A1 US2003176436 A1 US 2003176436A1
- Authority
- US
- United States
- Prior art keywords
- compound
- alkyl
- aryl
- heteroaryl
- arylalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract description 12
- 230000001580 bacterial effect Effects 0.000 title description 34
- 102100024746 Dihydrofolate reductase Human genes 0.000 title description 16
- 108020001096 dihydrofolate reductase Proteins 0.000 title description 16
- 239000003112 inhibitor Substances 0.000 title description 9
- 238000011282 treatment Methods 0.000 claims abstract description 25
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 11
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 10
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 239
- 125000003118 aryl group Chemical group 0.000 claims description 94
- -1 alkylenedioxo Chemical group 0.000 claims description 89
- 125000001072 heteroaryl group Chemical group 0.000 claims description 74
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 61
- 239000000203 mixture Substances 0.000 claims description 57
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 54
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 48
- 125000003545 alkoxy group Chemical group 0.000 claims description 44
- 125000005843 halogen group Chemical group 0.000 claims description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 31
- 125000005114 heteroarylalkoxy group Chemical group 0.000 claims description 31
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 28
- 125000004104 aryloxy group Chemical group 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 28
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 28
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 28
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 28
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 230000000844 anti-bacterial effect Effects 0.000 claims description 21
- 125000005309 thioalkoxy group Chemical group 0.000 claims description 21
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 19
- 239000003937 drug carrier Substances 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000004001 thioalkyl group Chemical group 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- FRASYFOHUKPWAC-UHFFFAOYSA-N N-hydroxy-N-sulfanylnitramide Chemical group ON(S)[N+]([O-])=O FRASYFOHUKPWAC-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 230000002421 anti-septic effect Effects 0.000 abstract description 6
- 239000000645 desinfectant Substances 0.000 abstract description 5
- 229940064004 antiseptic throat preparations Drugs 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 47
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 17
- 235000002639 sodium chloride Nutrition 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 0 [14*]C1=*C2=C(N=C1)N=C(N)N=C2N.[14*]C1=NC2=C(*=C1)C(N)=NC(N)=N2 Chemical compound [14*]C1=*C2=C(N=C1)N=C(N)N=C2N.[14*]C1=NC2=C(*=C1)C(N)=NC(N)=N2 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 244000005700 microbiome Species 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- HNXQXTQTPAJEJL-UHFFFAOYSA-N 2-aminopteridin-4-ol Chemical class C1=CN=C2NC(N)=NC(=O)C2=N1 HNXQXTQTPAJEJL-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 8
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 208000035473 Communicable disease Diseases 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241000606768 Haemophilus influenzae Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 208000019206 urinary tract infection Diseases 0.000 description 6
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 241000295644 Staphylococcaceae Species 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
- 239000012038 nucleophile Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 230000000269 nucleophilic effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000000612 proton pump inhibitor Substances 0.000 description 4
- 229940126409 proton pump inhibitor Drugs 0.000 description 4
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical class N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- OOBZBWBDZJAZPY-UHFFFAOYSA-N 6-[(3,5-dichloroanilino)methyl]pteridine-2,4-diamine Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC(Cl)=CC(Cl)=C1 OOBZBWBDZJAZPY-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NSIBULQOMYMLCB-UHFFFAOYSA-N CCC(C1=C2C=CC=CC2=CC=C1)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CCC(C1=C2C=CC=CC2=CC=C1)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 NSIBULQOMYMLCB-UHFFFAOYSA-N 0.000 description 3
- UJSWKPSTYAWJPJ-UHFFFAOYSA-N CN(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC([N+](=O)[O-])=CC=C1 Chemical compound CN(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC([N+](=O)[O-])=CC=C1 UJSWKPSTYAWJPJ-UHFFFAOYSA-N 0.000 description 3
- 241000588921 Enterobacteriaceae Species 0.000 description 3
- 241000588655 Moraxella catarrhalis Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000589516 Pseudomonas Species 0.000 description 3
- 229930189077 Rifamycin Natural products 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 229940126575 aminoglycoside Drugs 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- 239000003429 antifungal agent Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 3
- DRYYOLGDWVJUCL-UHFFFAOYSA-N pyrimidin-2-ylcyanamide Chemical compound N#CNC1=NC=CC=N1 DRYYOLGDWVJUCL-UHFFFAOYSA-N 0.000 description 3
- BTVYFIMKUHNOBZ-QXMMDKDBSA-N rifamycin s Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C\C(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C(C)C(OC)\C=C/OC1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-QXMMDKDBSA-N 0.000 description 3
- 229940081192 rifamycins Drugs 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 3
- 229960001082 trimethoprim Drugs 0.000 description 3
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 3
- 229960001099 trimetrexate Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- IHJBYRAXZVHUGF-UHFFFAOYSA-N 6-(chloromethyl)pteridine-2,4-diamine Chemical compound N1=C(CCl)C=NC2=NC(N)=NC(N)=C21 IHJBYRAXZVHUGF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 2
- SCZRQWDWRZYNFX-UHFFFAOYSA-N CC(C1=CC=C(Cl)C2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=CC=C(Cl)C2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 SCZRQWDWRZYNFX-UHFFFAOYSA-N 0.000 description 2
- FVWVQIHOWCNZMJ-UHFFFAOYSA-N CC(C1=CSC2=C1C=CC=C2)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=CSC2=C1C=CC=C2)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 FVWVQIHOWCNZMJ-UHFFFAOYSA-N 0.000 description 2
- VAPLSQGTDJSPQP-UHFFFAOYSA-N CC1=C(CCCN(C2=NC3=NC(N)=NC(N)=C3C=N2)C(C)C2=CC=CC3=CC=CC=C32)C=NN1 Chemical compound CC1=C(CCCN(C2=NC3=NC(N)=NC(N)=C3C=N2)C(C)C2=CC=CC3=CC=CC=C32)C=NN1 VAPLSQGTDJSPQP-UHFFFAOYSA-N 0.000 description 2
- TXQBOYFONZZTNX-UHFFFAOYSA-N CC1=C(NCC2=NC3=C(N)N=C(N)N=C3N=C2)C=C(C(F)(F)F)C=C1 Chemical compound CC1=C(NCC2=NC3=C(N)N=C(N)N=C3N=C2)C=C(C(F)(F)F)C=C1 TXQBOYFONZZTNX-UHFFFAOYSA-N 0.000 description 2
- ICJGICHYKQVUDD-UHFFFAOYSA-N CC1=CC=C(C(C)N(C)C2=NC3=NC(N)=NC(N)=C3C=N2)C2=CC=CC=C12 Chemical compound CC1=CC=C(C(C)N(C)C2=NC3=NC(N)=NC(N)=C3C=N2)C2=CC=CC=C12 ICJGICHYKQVUDD-UHFFFAOYSA-N 0.000 description 2
- JEKCSLMWKCKDCC-UHFFFAOYSA-N CC1=CC=C2N=C(C)SC2=C1 Chemical compound CC1=CC=C2N=C(C)SC2=C1 JEKCSLMWKCKDCC-UHFFFAOYSA-N 0.000 description 2
- LJKGIVZYZRGNGA-SNVBAGLBSA-N CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)[C@H](C)C1=CSC2=C1C=CC=C2 Chemical compound CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)[C@H](C)C1=CSC2=C1C=CC=C2 LJKGIVZYZRGNGA-SNVBAGLBSA-N 0.000 description 2
- SYNHYXZUIGUQRN-UHFFFAOYSA-N CCOC1=C(CN(C)C2=NC3=NC(N)=NC(N)=C3C=N2)C2=CC=CC=C2C=C1 Chemical compound CCOC1=C(CN(C)C2=NC3=NC(N)=NC(N)=C3C=N2)C2=CC=CC=C2C=C1 SYNHYXZUIGUQRN-UHFFFAOYSA-N 0.000 description 2
- NSIBULQOMYMLCB-MRXNPFEDSA-N CC[C@H](C1=CC=CC2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC[C@H](C1=CC=CC2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 NSIBULQOMYMLCB-MRXNPFEDSA-N 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 241000495778 Escherichia faecalis Species 0.000 description 2
- 206010017964 Gastrointestinal infection Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- IVKFBSYWIIUSFB-UHFFFAOYSA-N NC1=NC(N)=C2N=C(CNC3=C4C=CC=CC4=C(Cl)C=C3)C=NC2=N1 Chemical compound NC1=NC(N)=C2N=C(CNC3=C4C=CC=CC4=C(Cl)C=C3)C=NC2=N1 IVKFBSYWIIUSFB-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101100512165 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) mic-33 gene Proteins 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010037596 Pyelonephritis Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010048038 Wound infection Diseases 0.000 description 2
- VDALUGFDPYRBTC-UHFFFAOYSA-N [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC(OCC2=CC=CC=C2)=CC=C1 Chemical compound [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC(OCC2=CC=CC=C2)=CC=C1 VDALUGFDPYRBTC-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000005997 bromomethyl group Chemical group 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 229960000285 ethambutol Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960003350 isoniazid Drugs 0.000 description 2
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 150000002960 penicillins Chemical class 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 2
- 229960004659 ticarcillin Drugs 0.000 description 2
- 229960000707 tobramycin Drugs 0.000 description 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BCLCKENDTZITFB-UHFFFAOYSA-N 2-methyl-5-(trifluoromethyl)aniline Chemical compound CC1=CC=C(C(F)(F)F)C=C1N BCLCKENDTZITFB-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UQRLKWGPEVNVHT-UHFFFAOYSA-N 3,5-dichloroaniline Chemical compound NC1=CC(Cl)=CC(Cl)=C1 UQRLKWGPEVNVHT-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- CXYLLFGNJJCGHM-UHFFFAOYSA-N 4-amino-2-bromopyrimidine-5-carbonitrile Chemical compound NC1=NC(Br)=NC=C1C#N CXYLLFGNJJCGHM-UHFFFAOYSA-N 0.000 description 1
- DEPDZGNUVOAZCW-UHFFFAOYSA-N 4-chloronaphthalen-1-amine Chemical compound C1=CC=C2C(N)=CC=C(Cl)C2=C1 DEPDZGNUVOAZCW-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003757 Atypical pneumonia Diseases 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 241001148536 Bacteroides sp. Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- YQDWWMYDYQKWAA-UHFFFAOYSA-N C.C.C.C.[H]N(C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)C1=CC=C(O)C=C1.[H]N(CC1=CC=CC=N1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1.[H]N(CC1=CC=CN=C1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1.[H]N(CC1=CC=NC=C1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1.[H]N(CCCCN)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 Chemical compound C.C.C.C.[H]N(C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)C1=CC=C(O)C=C1.[H]N(CC1=CC=CC=N1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1.[H]N(CC1=CC=CN=C1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1.[H]N(CC1=CC=NC=C1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1.[H]N(CCCCN)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 YQDWWMYDYQKWAA-UHFFFAOYSA-N 0.000 description 1
- LAALUKTYOUMOSA-UHFFFAOYSA-N C.CC(C)C1=CC([N+](=O)[O-])=CC=C1N Chemical compound C.CC(C)C1=CC([N+](=O)[O-])=CC=C1N LAALUKTYOUMOSA-UHFFFAOYSA-N 0.000 description 1
- GXXQYOXUEPDRGO-UHFFFAOYSA-N C=CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)C(C)C1=C2C=CC=CC2=CC=C1 Chemical compound C=CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)C(C)C1=C2C=CC=CC2=CC=C1 GXXQYOXUEPDRGO-UHFFFAOYSA-N 0.000 description 1
- DPJZVAUIKGGYOI-UHFFFAOYSA-N C=CCN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC=CC=C1 Chemical compound C=CCN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC=CC=C1 DPJZVAUIKGGYOI-UHFFFAOYSA-N 0.000 description 1
- IRXFHWXHGPHQSZ-UHFFFAOYSA-N CC(=N)N.CC1=NC(N)=C(C#N)C(C)=N1.CC1=NC2=NC(N)=NC(N)=C2C(C)=N1.CCOC(C)=C(C#N)C#N.N=C(N)N Chemical compound CC(=N)N.CC1=NC(N)=C(C#N)C(C)=N1.CC1=NC2=NC(N)=NC(N)=C2C(C)=N1.CCOC(C)=C(C#N)C#N.N=C(N)N IRXFHWXHGPHQSZ-UHFFFAOYSA-N 0.000 description 1
- LSNMDLKVJFLHEN-UHFFFAOYSA-N CC(C)C1=CC([N+](=O)[O-])=CC=C1N Chemical compound CC(C)C1=CC([N+](=O)[O-])=CC=C1N LSNMDLKVJFLHEN-UHFFFAOYSA-N 0.000 description 1
- AHYPNEOHBIJKOO-UHFFFAOYSA-N CC(C1=C2C=CC=CC2=C(Cl)C=C1)N(CC1CC1)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=C2C=CC=CC2=C(Cl)C=C1)N(CC1CC1)C1=NC2=NC(N)=NC(N)=C2C=N1 AHYPNEOHBIJKOO-UHFFFAOYSA-N 0.000 description 1
- HQWSVBVFEQNGBN-UHFFFAOYSA-N CC(C1=C2C=CC=CC2=CC(Cl)=C1)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=C2C=CC=CC2=CC(Cl)=C1)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 HQWSVBVFEQNGBN-UHFFFAOYSA-N 0.000 description 1
- KGXXHSFZAHSLGF-UHFFFAOYSA-N CC(C1=C2C=CC=CC2=CC=C1)N(CCC(C)(C)C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=C2C=CC=CC2=CC=C1)N(CCC(C)(C)C)C1=NC2=NC(N)=NC(N)=C2C=N1 KGXXHSFZAHSLGF-UHFFFAOYSA-N 0.000 description 1
- QFOMNRBLLCANJY-UHFFFAOYSA-N CC(C1=C2C=CC=CC2=CC=C1)N(CCC1=CC=C(Cl)C=C1)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=C2C=CC=CC2=CC=C1)N(CCC1=CC=C(Cl)C=C1)C1=NC2=NC(N)=NC(N)=C2C=N1 QFOMNRBLLCANJY-UHFFFAOYSA-N 0.000 description 1
- SFNJGKLMTVIEKE-UHFFFAOYSA-N CC(C1=C2C=CC=CC2=CC=C1)N(CCCCO)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=C2C=CC=CC2=CC=C1)N(CCCCO)C1=NC2=NC(N)=NC(N)=C2C=N1 SFNJGKLMTVIEKE-UHFFFAOYSA-N 0.000 description 1
- MDWUOVOKVPYVDJ-UHFFFAOYSA-N CC(C1=C2C=CC=CC2=NC=C1)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=C2C=CC=CC2=NC=C1)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 MDWUOVOKVPYVDJ-UHFFFAOYSA-N 0.000 description 1
- GKBLKCKBBQZWAK-UHFFFAOYSA-N CC(C1=C2CCCCC2=CC2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=C2CCCCC2=CC2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 GKBLKCKBBQZWAK-UHFFFAOYSA-N 0.000 description 1
- ZQKAVVSLDJPQKF-UHFFFAOYSA-N CC(C1=C2CCCCC2=CC2=CC=CC=C21)N(CC1CC1)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=C2CCCCC2=CC2=CC=CC=C21)N(CC1CC1)C1=NC2=NC(N)=NC(N)=C2C=N1 ZQKAVVSLDJPQKF-UHFFFAOYSA-N 0.000 description 1
- PNIPSNMJPKASOK-UHFFFAOYSA-N CC(C1=CC=C(F)C2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=CC=C(F)C2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 PNIPSNMJPKASOK-UHFFFAOYSA-N 0.000 description 1
- WRQAZOUOIFMEEU-UHFFFAOYSA-N CC(C1=CC=C(OCC2=C(F)C=CC=C2Cl)C=C1)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=CC=C(OCC2=C(F)C=CC=C2Cl)C=C1)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 WRQAZOUOIFMEEU-UHFFFAOYSA-N 0.000 description 1
- QFRGEQPJYQAJBM-UHFFFAOYSA-N CC(C1=CC=C2CCC3=C2C1=CC=C3)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=CC=C2CCC3=C2C1=CC=C3)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 QFRGEQPJYQAJBM-UHFFFAOYSA-N 0.000 description 1
- FXNXRFZABDBVSV-UHFFFAOYSA-N CC(C1=CC=CC2=C1C=CC=C2)N(CCC1=CC=CC=C1)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=CC=CC2=C1C=CC=C2)N(CCC1=CC=CC=C1)C1=NC2=NC(N)=NC(N)=C2C=N1 FXNXRFZABDBVSV-UHFFFAOYSA-N 0.000 description 1
- DYTXPCDXWNIZJS-UHFFFAOYSA-N CC(C1=CC=CC2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=CC=CC2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 DYTXPCDXWNIZJS-UHFFFAOYSA-N 0.000 description 1
- BLFPPXNOFNUBNE-UHFFFAOYSA-N CC(C1=CC=CC2=CC=CC=C21)N(CCC1=CC=CC(F)=C1)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CC(C1=CC=CC2=CC=CC=C21)N(CCC1=CC=CC(F)=C1)C1=NC2=NC(N)=NC(N)=C2C=N1 BLFPPXNOFNUBNE-UHFFFAOYSA-N 0.000 description 1
- QSPRVEJGDHEDSV-UHFFFAOYSA-N CC(C1=CSC2=C1C=CC=C2)N(C)C1=NC2=C(C=N1)C(N)=NC(N)=N2.CNC(C)C1=CSC2=C1C=CC=C2.N=C(N)N.[C-]#[N+]C1=C(N)N=C(N(C)C(C)C2=CSC3=C2C=CC=C3)N=C1.[C-]#[N+]C1=CN=C(Br)N=C1N Chemical compound CC(C1=CSC2=C1C=CC=C2)N(C)C1=NC2=C(C=N1)C(N)=NC(N)=N2.CNC(C)C1=CSC2=C1C=CC=C2.N=C(N)N.[C-]#[N+]C1=C(N)N=C(N(C)C(C)C2=CSC3=C2C=CC=C3)N=C1.[C-]#[N+]C1=CN=C(Br)N=C1N QSPRVEJGDHEDSV-UHFFFAOYSA-N 0.000 description 1
- CAEGRJIMQCUODS-UHFFFAOYSA-N CC1=CC=C(C(C)N(C)C2=NC3=C(C=N2)C(N)=NC(N)=N3)C2=C1C=CC=C2.CNC(C)C1=CC=C(C)C2=C1C=CC=C2.N=C(N)N.[C-]#[N+]C1=C(N)N=C(N(C)C(C)C2=CC=C(C)C3=C2C=CC=C3)N=C1.[C-]#[N+]C1=CN=C(Br)N=C1N Chemical compound CC1=CC=C(C(C)N(C)C2=NC3=C(C=N2)C(N)=NC(N)=N3)C2=C1C=CC=C2.CNC(C)C1=CC=C(C)C2=C1C=CC=C2.N=C(N)N.[C-]#[N+]C1=C(N)N=C(N(C)C(C)C2=CC=C(C)C3=C2C=CC=C3)N=C1.[C-]#[N+]C1=CN=C(Br)N=C1N CAEGRJIMQCUODS-UHFFFAOYSA-N 0.000 description 1
- BXBXDHMZWPCWEV-UHFFFAOYSA-N CC1=CC=C(C(C)N(CC2CC2)C2=NC3=NC(N)=NC(N)=C3C=N2)C2=CC=CC=C12 Chemical compound CC1=CC=C(C(C)N(CC2CC2)C2=NC3=NC(N)=NC(N)=C3C=N2)C2=CC=CC=C12 BXBXDHMZWPCWEV-UHFFFAOYSA-N 0.000 description 1
- RPWXDLQUSKLGNG-UHFFFAOYSA-N CC1=CC=C(C(F)(F)F)C=C1N.CC1=CC=C(C(F)(F)F)C=C1NCC1=NC2=C(N=C1)N=C(N)N=C2N.NC1=NC(N)=C2N=C(CCl)C=NC2=N1 Chemical compound CC1=CC=C(C(F)(F)F)C=C1N.CC1=CC=C(C(F)(F)F)C=C1NCC1=NC2=C(N=C1)N=C(N)N=C2N.NC1=NC(N)=C2N=C(CCl)C=NC2=N1 RPWXDLQUSKLGNG-UHFFFAOYSA-N 0.000 description 1
- BXBXDHMZWPCWEV-CQSZACIVSA-N CC1=CC=C([C@@H](C)N(CC2CC2)C2=NC3=NC(N)=NC(N)=C3C=N2)C2=CC=CC=C12 Chemical compound CC1=CC=C([C@@H](C)N(CC2CC2)C2=NC3=NC(N)=NC(N)=C3C=N2)C2=CC=CC=C12 BXBXDHMZWPCWEV-CQSZACIVSA-N 0.000 description 1
- GXWPEBXOPCSBBW-UHFFFAOYSA-M CCC(=O)C1=C2C=CC=CC2=CC=C1.CCC(C1=C2C=CC=CC2=CC=C1)N(C)C1=NC2=C(C=N1)C(N)=NC(N)=N2.CCC(NC)C1=C2C=CC=CC2=CC=C1.CCC(O)C1=C2C=CC=CC2=CC=C1.CC[Mg]Br.CN.N=C(N)N.O=CC1=C2C=CC=CC2=CC=C1.[C-]#[N+]C1=C(N)N=C(N(C)C(CC)C2=C3C=CC=CC3=CC=C2)N=C1.[C-]#[N+]C1=CN=C(Br)N=C1N Chemical compound CCC(=O)C1=C2C=CC=CC2=CC=C1.CCC(C1=C2C=CC=CC2=CC=C1)N(C)C1=NC2=C(C=N1)C(N)=NC(N)=N2.CCC(NC)C1=C2C=CC=CC2=CC=C1.CCC(O)C1=C2C=CC=CC2=CC=C1.CC[Mg]Br.CN.N=C(N)N.O=CC1=C2C=CC=CC2=CC=C1.[C-]#[N+]C1=C(N)N=C(N(C)C(CC)C2=C3C=CC=CC3=CC=C2)N=C1.[C-]#[N+]C1=CN=C(Br)N=C1N GXWPEBXOPCSBBW-UHFFFAOYSA-M 0.000 description 1
- IHKBTSFIWFIGBC-UHFFFAOYSA-N CCC(C1=CC=C(Cl)C2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CCC(C1=CC=C(Cl)C2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 IHKBTSFIWFIGBC-UHFFFAOYSA-N 0.000 description 1
- RUMGHNKPLKCDSU-UHFFFAOYSA-N CCC(C1=CC=C(F)C2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CCC(C1=CC=C(F)C2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 RUMGHNKPLKCDSU-UHFFFAOYSA-N 0.000 description 1
- PGHKDJSPXOQWGV-UHFFFAOYSA-N CCC1=C(C(C)N(C)C2=NC3=NC(N)=NC(N)=C3C=N2)C2=CC=CC=C2C=C1 Chemical compound CCC1=C(C(C)N(C)C2=NC3=NC(N)=NC(N)=C3C=N2)C2=CC=CC=C2C=C1 PGHKDJSPXOQWGV-UHFFFAOYSA-N 0.000 description 1
- IFQDZPSRQNOYKZ-UHFFFAOYSA-N CCC1=CC2=CC(C(C)N(CC3CC3)C3=NC4=NC(N)=NC(N)=C4C=N3)=CC=C2C=C1 Chemical compound CCC1=CC2=CC(C(C)N(CC3CC3)C3=NC4=NC(N)=NC(N)=C4C=N3)=CC=C2C=C1 IFQDZPSRQNOYKZ-UHFFFAOYSA-N 0.000 description 1
- DYJRNSOOYYZNAE-UHFFFAOYSA-N CCC1=NC2=NC(N)=NC(N)=C2N=C1.NC1=NC(N)=C2N=CC(CCl)=NC2=N1 Chemical compound CCC1=NC2=NC(N)=NC(N)=C2N=C1.NC1=NC(N)=C2N=CC(CCl)=NC2=N1 DYJRNSOOYYZNAE-UHFFFAOYSA-N 0.000 description 1
- ZHPYYASRGYTATL-UHFFFAOYSA-N CCCC(C1=CC=CC2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound CCCC(C1=CC=CC2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 ZHPYYASRGYTATL-UHFFFAOYSA-N 0.000 description 1
- YWTUYGQZODIOAY-UHFFFAOYSA-N CCCN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC=CC=C1 Chemical compound CCCN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC=CC=C1 YWTUYGQZODIOAY-UHFFFAOYSA-N 0.000 description 1
- LNCKCVAUHJURSV-UHFFFAOYSA-N CCCN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC=CC=C1.[HH] Chemical compound CCCN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC=CC=C1.[HH] LNCKCVAUHJURSV-UHFFFAOYSA-N 0.000 description 1
- GQPSXHWQGIYBOV-UHFFFAOYSA-N CCCOCCN(C1=NC2=NC(N)=NC(N)=C2C=N1)C(C)C1=CC=CC2=CC=CC=C21 Chemical compound CCCOCCN(C1=NC2=NC(N)=NC(N)=C2C=N1)C(C)C1=CC=CC2=CC=CC=C21 GQPSXHWQGIYBOV-UHFFFAOYSA-N 0.000 description 1
- PXNFEEJRELKSCL-UHFFFAOYSA-N CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)C(C)C1=CC=C(C)C2=CC=CC=C21 Chemical compound CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)C(C)C1=CC=C(C)C2=CC=CC=C21 PXNFEEJRELKSCL-UHFFFAOYSA-N 0.000 description 1
- IWCVNXQFKGSVEL-UHFFFAOYSA-N CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)C(C)C1=CC=CC2=CC=CC=C21 Chemical compound CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)C(C)C1=CC=CC2=CC=CC=C21 IWCVNXQFKGSVEL-UHFFFAOYSA-N 0.000 description 1
- PXNFEEJRELKSCL-CYBMUJFWSA-N CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)[C@H](C)C1=CC=C(C)C2=CC=CC=C21 Chemical compound CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)[C@H](C)C1=CC=C(C)C2=CC=CC=C21 PXNFEEJRELKSCL-CYBMUJFWSA-N 0.000 description 1
- ONRCKMXCHKARQM-LLVKDONJSA-N CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)[C@H](C)C1=CC=C(F)C2=CC=CC=C21 Chemical compound CCN(C1=NC2=NC(N)=NC(N)=C2C=N1)[C@H](C)C1=CC=C(F)C2=CC=CC=C21 ONRCKMXCHKARQM-LLVKDONJSA-N 0.000 description 1
- CUFFCXNQWBOXCH-UHFFFAOYSA-N CN(C)CC1=NC2=C(N)N=C(N)N=C2N=C1.NC1=NC(N)=C2N=C(CCl)C=NC2=N1 Chemical compound CN(C)CC1=NC2=C(N)N=C(N)N=C2N=C1.NC1=NC(N)=C2N=C(CCl)C=NC2=N1 CUFFCXNQWBOXCH-UHFFFAOYSA-N 0.000 description 1
- CMGMRTNWNJMOJV-UHFFFAOYSA-N CN(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC=CC=C1 Chemical compound CN(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC=CC=C1 CMGMRTNWNJMOJV-UHFFFAOYSA-N 0.000 description 1
- FBFNJDZYIIOJMK-UHFFFAOYSA-N COC(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 Chemical compound COC(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 FBFNJDZYIIOJMK-UHFFFAOYSA-N 0.000 description 1
- PNIPSNMJPKASOK-JTQLQIEISA-N C[C@@H](C1=CC=C(F)C2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound C[C@@H](C1=CC=C(F)C2=CC=CC=C21)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 PNIPSNMJPKASOK-JTQLQIEISA-N 0.000 description 1
- DYTXPCDXWNIZJS-LLVKDONJSA-N C[C@H](C1=C2C=CC=CC2=CC=C1)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound C[C@H](C1=C2C=CC=CC2=CC=C1)N(C)C1=NC2=NC(N)=NC(N)=C2C=N1 DYTXPCDXWNIZJS-LLVKDONJSA-N 0.000 description 1
- GKWCUBUZDYYCDY-LLVKDONJSA-N C[C@H](C1=CSC2=C1C=CC=C2)N(CC1CC1)C1=NC2=NC(N)=NC(N)=C2C=N1 Chemical compound C[C@H](C1=CSC2=C1C=CC=C2)N(CC1CC1)C1=NC2=NC(N)=NC(N)=C2C=N1 GKWCUBUZDYYCDY-LLVKDONJSA-N 0.000 description 1
- ZYOSMCVXJBAQCV-UHFFFAOYSA-N C[ClH]Cc1nc2c(N)nc(N)nc2nc1 Chemical compound C[ClH]Cc1nc2c(N)nc(N)nc2nc1 ZYOSMCVXJBAQCV-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KECHYAFVYLLNCH-UHFFFAOYSA-O Cc(cc1)cc2c1nc([SH2+])[s]2 Chemical compound Cc(cc1)cc2c1nc([SH2+])[s]2 KECHYAFVYLLNCH-UHFFFAOYSA-O 0.000 description 1
- REAAEBYFEUTBCY-UHFFFAOYSA-N Cc1c(CNc2cccc([NH+]([O-])[O-])c2)cnc2nc(N)nc(N)c12 Chemical compound Cc1c(CNc2cccc([NH+]([O-])[O-])c2)cnc2nc(N)nc(N)c12 REAAEBYFEUTBCY-UHFFFAOYSA-N 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010062631 Cholecystitis infective Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010014671 Endocarditis enterococcal Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 241000207201 Gardnerella vaginalis Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010018693 Granuloma inguinale Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 208000028861 Helicobacter pylori infectious disease Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- 206010023424 Kidney infection Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241001534216 Klebsiella granulomatis Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010024971 Lower respiratory tract infections Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- OKMFHVVSJGHRBM-UHFFFAOYSA-N NC1=C2C=CC=CC2=C(Cl)C=C1.NC1=NC2=C(N=C(CCl)C=N2)C(N)=N1.NC1=NC2=C(N=C(CNC3=C4C=CC=CC4=C(Cl)C=C3)C=N2)C(N)=N1 Chemical compound NC1=C2C=CC=CC2=C(Cl)C=C1.NC1=NC2=C(N=C(CCl)C=N2)C(N)=N1.NC1=NC2=C(N=C(CNC3=C4C=CC=CC4=C(Cl)C=C3)C=N2)C(N)=N1 OKMFHVVSJGHRBM-UHFFFAOYSA-N 0.000 description 1
- RDPAJININCHROO-UHFFFAOYSA-N NC1=CC=C([N+](=O)[O-])C=C1OCC1=NC2=C(N=C1)N=C(N)N=C2N Chemical compound NC1=CC=C([N+](=O)[O-])C=C1OCC1=NC2=C(N=C1)N=C(N)N=C2N RDPAJININCHROO-UHFFFAOYSA-N 0.000 description 1
- ZRVQKKXVCGJKRR-UHFFFAOYSA-N NC1=NC(N)=C2C=NC(NCC3=CC=C(OC4=CC=C(F)C=C4)C=C3)=NC2=N1 Chemical compound NC1=NC(N)=C2C=NC(NCC3=CC=C(OC4=CC=C(F)C=C4)C=C3)=NC2=N1 ZRVQKKXVCGJKRR-UHFFFAOYSA-N 0.000 description 1
- CFBFQVIUCCPNNF-UHFFFAOYSA-N NC1=NC(N)=C2N=C(CCl)C=NC2=N1.[H]N(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC(Cl)=CC(Cl)=C1 Chemical compound NC1=NC(N)=C2N=C(CCl)C=NC2=N1.[H]N(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC(Cl)=CC(Cl)=C1 CFBFQVIUCCPNNF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 206010028885 Necrotising fasciitis Diseases 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 229930195708 Penicillin V Natural products 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035718 Pneumonia legionella Diseases 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010061372 Streptococcal infection Diseases 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 206010046477 Urethral syndrome Diseases 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- OPUUPOZRLORBMU-UHFFFAOYSA-N [H]N(C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)C1=CC=C(O)C=C1 Chemical compound [H]N(C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1)C1=CC=C(O)C=C1 OPUUPOZRLORBMU-UHFFFAOYSA-N 0.000 description 1
- IDVNPVBQNTZCLV-UHFFFAOYSA-N [H]N(CC1=C(C)C2=C(N)N=C(N)N=C2N=C1)C1=CC([N+](=O)[O-])=CC=C1 Chemical compound [H]N(CC1=C(C)C2=C(N)N=C(N)N=C2N=C1)C1=CC([N+](=O)[O-])=CC=C1 IDVNPVBQNTZCLV-UHFFFAOYSA-N 0.000 description 1
- LNLQYYCOMNCMTF-UHFFFAOYSA-N [H]N(CC1=CC2=C(N)N=C(N)N=C2N=C1)C1=CC([N+](=O)[O-])=CC=C1 Chemical compound [H]N(CC1=CC2=C(N)N=C(N)N=C2N=C1)C1=CC([N+](=O)[O-])=CC=C1 LNLQYYCOMNCMTF-UHFFFAOYSA-N 0.000 description 1
- LJXOQDYEYKWWQM-UHFFFAOYSA-N [H]N(CC1=CC=CC=N1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 Chemical compound [H]N(CC1=CC=CC=N1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 LJXOQDYEYKWWQM-UHFFFAOYSA-N 0.000 description 1
- NLTXVNCSAYQZGD-UHFFFAOYSA-N [H]N(CC1=CC=CN=C1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 Chemical compound [H]N(CC1=CC=CN=C1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 NLTXVNCSAYQZGD-UHFFFAOYSA-N 0.000 description 1
- RLRVIGPNOTXLEP-UHFFFAOYSA-N [H]N(CC1=CC=NC=C1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 Chemical compound [H]N(CC1=CC=NC=C1)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 RLRVIGPNOTXLEP-UHFFFAOYSA-N 0.000 description 1
- BRDISRXMVPORLN-UHFFFAOYSA-N [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC([N+](=O)[O-])=C(F)C=C1 Chemical compound [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC([N+](=O)[O-])=C(F)C=C1 BRDISRXMVPORLN-UHFFFAOYSA-N 0.000 description 1
- PWILJXGPGYBYHV-UHFFFAOYSA-N [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC2=C(C=C1)N=C(S)S2 Chemical compound [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC2=C(C=C1)N=C(S)S2 PWILJXGPGYBYHV-UHFFFAOYSA-N 0.000 description 1
- DKLSUYVDWJDBCR-UHFFFAOYSA-N [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC2=C(C=C1)OCO2 Chemical compound [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC2=C(C=C1)OCO2 DKLSUYVDWJDBCR-UHFFFAOYSA-N 0.000 description 1
- JDQNWPMKJJDFDO-UHFFFAOYSA-N [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC=C([N+](=O)[O-])C=C1O Chemical compound [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC=C([N+](=O)[O-])C=C1O JDQNWPMKJJDFDO-UHFFFAOYSA-N 0.000 description 1
- HSWOOFSUCOVAGE-UHFFFAOYSA-N [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC=CC(N(=O)O)=C1 Chemical compound [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC=CC(N(=O)O)=C1 HSWOOFSUCOVAGE-UHFFFAOYSA-N 0.000 description 1
- KWBYHDAETXMHLI-UHFFFAOYSA-N [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC=CC=C1 Chemical compound [H]N(CC1=NC2=C(N=C1)N=C(N)N=C2N)C1=CC=CC=C1 KWBYHDAETXMHLI-UHFFFAOYSA-N 0.000 description 1
- LCTZWNAKISMPCD-UHFFFAOYSA-N [H]N(CCCCN)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 Chemical compound [H]N(CCCCN)C(=O)C1=CC=C(N(C)CC2=NC3=C(N=C2)N=C(N)N=C3N)C=C1 LCTZWNAKISMPCD-UHFFFAOYSA-N 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000013086 acute epiglottitis Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 208000002479 balanitis Diseases 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000003781 beta lactamase inhibitor Substances 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000011208 chromatographic data Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 208000001606 epiglottitis Diseases 0.000 description 1
- 208000004000 erythrasma Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000001581 lymphogranuloma venereum Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- 150000004002 naphthaldehydes Chemical class 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000007970 necrotizing fasciitis Diseases 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940056367 penicillin v Drugs 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- BPLBGHOLXOTWMN-MBNYWOFBSA-N phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-M pivalate Chemical compound CC(C)(C)C([O-])=O IUGYQRQAERSCNH-UHFFFAOYSA-M 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000004537 potential cytotoxicity Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- CRSSOWURPVSKTG-UHFFFAOYSA-N pteridine-2,4-diamine;hydrochloride Chemical compound Cl.N1=CC=NC2=NC(N)=NC(N)=C21 CRSSOWURPVSKTG-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- NFHMDRANESJFQS-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine-2,4-diamine Chemical group N1=CN=CC2=NC(N)=NC(N)=C21 NFHMDRANESJFQS-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004014 thioethyl group Chemical group [H]SC([H])([H])C([H])([H])* 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- This invention relates to novel heterocyclic compounds and to their use, for example, in the prophylaxis and or medical treatment of bacterial infections, and their use as antiseptics, sterilizants, or disinfectants.
- the invention relates to heterocyclic compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions.
- the compounds and compositions comprising them are useful for treating disease or disease symptoms.
- the invention also provides for methods of making the compounds and methods for identifying compounds with desired biological activity.
- the invention is based on the discovery that certain heterocyclic compounds have potent antibacterial activity.
- this invention relates to novel heterocyclic compounds and to their use in the prophylaxis and/or medical treatment of bacterial infections or as antiseptics, sterilizants, or disinfectants.
- the invention is further based on the discovery that certain heterocyclic compounds, including in general, substituted pteridinyl, quinazolinyl and pyrimidopyrimidinyl heterocycles, have potent antibacterial activity and are useful in the treatment of a variety of human diseases and microbial infections.
- heterocyclic compounds show selective inhibition of bacterial dihydrofolate reductase (bDHFR) versus human DHFR (hDHFR)
- the compounds of the invention can be useful in the treatment of microbial infections without human toxicity associated with inhibition of hDHFR.
- A is N, CH, or CR 15 ;
- R 14 is —(CH 2 ) n —X—Y, wherein n is 1, 2, 3, 4, 5, or 6;
- X is O, NH, or NR 15 ;
- Y is aryl or heteroaryl, wherein each Y is optionally substituted with 1-4 independent R 16 .
- Each R 15 is independently lower alkyl; each R 16 is independently halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R 15 , S(O) 2 NR 17 R 17 , S(O) 2 R 17 , C(O)OR 18 , C(O)NH 2 , or C(O)NR 19 R 20 ; each R 17 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluor
- this invention relates to a compound of the following formula:
- A is N, CH, or CR 15 ; each R 14 is independently —(CH 2 ) n —X—Y, wherein n is 1, 2, 3, 4, 5, or 6; X is O, NH, or NR 15 ; and Y is aryl or heteroaryl, wherein each Y is optionally substituted with 1-4 independent R 16 .
- Each R 15 is independently lower alkyl; each R 16 is independently halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R 15 , S(O) 2 NR 17 R 17 , S(O) 2 R 17 , C(O)OR 18 , C(O)NH 2 , or C(O)NR 19 R 20 ; each R 17 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluor
- halo refers to any radical of fluorine, chlorine, bromine or iodine.
- alkyl refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C 1 -C 10 indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it.
- lower alkyl refers to a C 1 -C 8 alkyl chain.
- alkoxy refers to an —O-alkyl radical.
- alkylene refers to a divalent alkyl (i.e., —R—).
- alkylenedioxo refers to a divalent species of the structure —O—R—O—, in which R represents an alkylene.
- aminoalkyl refers to an alkyl substituted with an amino.
- mercapto refers to an —SH radical.
- thioalkoxy refers to an —S-alkyl radical.
- aryl refers to a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent. Examples of aryl groups include phenyl, naphthyl and the like.
- arylalkyl or the term “aralkyl” refers to alkyl substituted with an aryl.
- arylalkoxy refers to an alkoxy substituted with aryl.
- heteroaryl refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent.
- heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like.
- heteroarylalkyl or the term “heteroaralkyl” refers to an alkyl substituted with a heteroaryl.
- heteroarylalkoxy refers to an alkoxy substituted with heteroaryl.
- a carbon-, nitrogen-, sulfur- halogen- and/or oxygen-containing function group is a substituted or unsubstituted, linear, branched, or cyclic, alkyl, alkenyl, alkynyl, aryl, aralkyl, or alkaryl group, or a derivative of one or more of these groups where heteroatoms are substituted for one or more of the carbon and/or hydrogen atoms (e.g., amino groups, alkylamino groups, hydroxyl and alkoxyl groups, thiol groups, halogens, nitro groups, phenolic groups, or other substituted aromatic or aliphatic groups)).
- heteroatoms e.g., amino groups, alkylamino groups, hydroxyl and alkoxyl groups, thiol groups, halogens, nitro groups, phenolic groups, or other substituted aromatic or aliphatic groups
- Other embodiments include compounds of any of the formulae described herein wherein A is N; those wherein n is 1; those wherein Y is phenyl, optionally substituted with 1-4 independent R 16 ; those wherein Y is phenyl; those wherein Y is phenyl substituted with 1-4 independent R 16 ; those wherein Y is
- each R 16 is halo, alkyl, alkylenedioxo, aryl, aralkyl, nitro, hydroxy, mercapto, amine, alkoxy, arylalkoxy, or heteroarylalkoxy; those wherein Y is
- each R 16 is independently C(O)NR 19 R 20
- each R 19 is independently aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl
- each R 20 is independently aminoalkyl, aryl, or arylalkyl
- each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R 15 , C(O)OR 21 , C(O)NR 21 R 21 , S(O) 2 NR 21 R 21 ,
- n 1, and X is O; those wherein n is 1, X is NH or NR 15 , and R 15 is CH 3 ; those wherein n is 1, X is NH or NR 15 (R 15 is CH 3 ), and Y is phenyl, optionally substituted with 1-4 independent R 16 ; those wherein n is 1, X is NH or NR 15 , and R 15 is CH 3 , and Y is
- each R 16 being halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)OR 18 , C(O)NH 2 , or C(O)NR 19 R 20 ; and those wherein Y is phenyl (optionally substituted with 1-4 independent R 16 ) and A is N.
- n 1, X is O, and A is N; those wherein n is 1, X is O, Y is phenyl, optionally substituted with 1-4 independent R 16 ; those wherein n is 1, X is O, Y is phenyl substituted with 1-4 independent R 16 ; those wherein n is 1, X is NH or NR 15 (wherein R 15 is CH 3 ), A is N; those wherein n is 1, X is NH or NR 15 (wherein R 15 is CH 3 ), A is N, Y is phenyl, optionally substituted with 1-4 independent R 16 ; those wherein n is 1, X is NH or NR 15 (wherein R 15 is CH 3 ), A is N, Y is phenyl; those wherein n is 1, X is NH or NR 15 (wherein R 15 is CH 3 ), A is N, Y is phenyl; those wherein n is 1, X is NH or NR 15 (wherein R 15 is CH 3
- n 1, X is O, A is N, Y is phenyl, optionally substituted with 1-4 independent R 16 ; those wherein n is 1, X is O, A is N, Y is
- each R 16 is independently halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)OR 18 , C(O)NH 2 , or C(O)NR 19 R 20 ; those wherein n is 1, X is O, A is N, and Y is
- n 1, X is NH or NR 15 (R 15 is CH 3 ), A is N, Y is
- each R 16 being halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)OR 18 , C(O)NH 2 , or C(O)NR 19 R 20 ; those wherein n is 1, X is NH or NR 15 (R 15 is CH 3 ), A is N, Y is
- the invention relates to a compound having the formula:
- a and B are independently selected from the group consisting of N and CR 7 , wherein R 7 is hydrogen or a carbon-, nitrogen-, sulfur- halogen- and/or oxygen-containing function group;
- R 1 and R 2 are —NR 5 R 6 groups, wherein R 5 and R 6 are independently hydrogen or carbon-containing functional groups;
- R 3 is hydrogen
- R 4 is a carbon-, nitrogen-, sulfur-, halogen-, and/or oxygen-containing functional group
- R 4 is not —NH 2 , —N(H)(methyl), —N(H)(butyl), —N(H)(hexyl), —N(H)(phenyl), —N(H)(benzyl), —N(H)(NH 2 ), —N(H)(CH 2 CH 2 OH), —N(CH 2 CH 2 OH) 2 , phenyl, N-piperidinyl, or —S(ethyl);
- R 4 is not methyl, isobutyl, phenyl, 4-methylphenyl, 4-chlorophenyl, 4-bromophenyl, 2-(2,5-dimethoxyphenyl)-ethyl, or —CH(OCH 3 ) 2 ;
- R 4 is an amino group other than —NH 2 , (3,4-dichlorophenyl)methylamino, or (3,4-dichlorophenyl)methyleneimino.
- R 5 and R 6 are independently hydrogen
- a and B are each independently N;
- R 4 is NR 7 R 8 ;
- R 4 is NR 7 R 8 ;
- R 7 is C1-C6 alkyl substituted with aryl or heteroaryl
- R 8 is C1-C6 alkyl optionally substituted with alkenyl, hydroxyl, alkoxy, cycloalkyl, or aryl;
- R 7 is C1-C6 alkyl substituted with aryl
- R 8 is C1-C6 alkyl
- R 7 is C1-C6 alkyl substituted with heteroaryl
- R 8 is C1-C6 alkyl
- R 7 is C1-C6 alkyl substituted with aryl
- R 8 is C1-C6 alkyl substituted with hydroxyl or alkoxy
- R 4 is NR 7 R 8 ;
- R 4 is NR 7 R 8 ;
- R 7 is C1-C6 alkyl
- R 8 is C1-C6 alkyl substituted with cycloalkyl
- R 4 is NR 7 R 8 ;
- R 7 is independently C1-C6 alkyl substituted with aryl
- R 8 is independently C1-C6 alkyl substituted with aryl
- R 7 is hydrogen, alkyl, cycloalkyl, aryl, halogen, thioalkyl, hydroxy, alkoxy, amino, alkyl, or NR 5 R 6 ; wherein each R 5 and R 6 on the nitrogen atom independently is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroarylalkyl, or alkylcarbonyl;
- R 7 is C1-C6 alkyl substituted with naphthyl, which is optionally substituted with alkyl, halo, hydroxy, alkoxy, thioalkyl, or amino;
- R 8 is methyl or ethyl
- R 7 is C1-C6 alkyl substituted with benzothienyl, which is optionally substituted with alkyl, halo, hydroxy, alkoxy, thioalkyl, or amino;
- compositions having a compound of any of the formulae described herein and a pharmaceutically acceptable carrier; or a compound of any of the formulae described herein, an additional therapeutic agent, and a pharmaceutically acceptable carrier; or a compound of any of the formulae described herein, an additional therapeutic agent, and a pharmaceutically acceptable carrier, wherein the additional therapeutic agent is an antibacterial agent.
- Yet another aspect of this invention relates to a method of treating a subject (e.g., mammal) infected with one or more bacteria (including, but not limited to urinary tract infections, systemic and topical infections, sepsis, antibiotic mediated colitis, ulcers of the gastrointestinal tract, topical disinfectant, antiseptic, sterilizant, wound care, and surgical cleansing).
- the method includes administering to the subject (including a subject identified as in need of such treatment) an effective amount of a compound described herein, or a composition described herein to produce such effect.
- the compounds and compositions herein are also useful as antiparasitic agents.
- Another aspect of this invention relates to a method of treating a subject (e.g., a mammal) infected with one or more parasites.
- the method includes administering to the subject (including a subject identified as in need of such treatment) an effective amount of a compound described herein, or a composition described herein to treat parasites, or disease, infection, or symptoms thereof.
- the invention also relates to a method of making a compound described herein.
- the method includes taking a 2,4-diamino pteridinyl (or a 2,4-diaminopyrimidopyrimidinyl) compound and reacting it with one or more chemical reagents in one or more steps to produce a compound described herein.
- the method includes taking any one of the intermediate compounds described herein and reacting it with one or chemical reagents in one or more steps to produce a compound described herein.
- the invention further relates to a product (i.e., a compound of any of the formulae) made by the method described above.
- a method for identifying a compound having antibacterial activity which includes: a) assessing the structure of a compound of a formula herein; b) procuring a derivative compound of the compound from step a); and c) assessing the antibacterial activity of the derivative compound; and a method for identifying a compound having antibacterial activity which includes: a) taking a candidate compound; b) assessing the binding affinity of the candidate compound in a model of the DHFR (e.g., bDHFR, hDHFR) enzyme; and c) assessing the antibacterial activity of the candidate compound. Assessing antibacterial activity can be performed by a variety of procedures known in the art, including those delineated herein.
- a compound that can inhibit bacterial DHFR selectively over human DHFR can provide an advantageous treatment option for bacterial disease or disease symptoms.
- 6-substituted pteridines have been described in the literature as potent inhibitors of either human DHFR (e.g. methotrexate, used as anti-cancer agent) or bacterial DHFR (e.g. Trimetrexate used for treatment of bacterial and parastic infections),
- bacterial DHFR e.g. Trimetrexate used for treatment of bacterial and parastic infections
- Existing treatments with compounds such as trimetrexate have severe side effects and toxicities associated with inhibition of DHFR.
- the compounds in this invention are potent bDHFR inhibitors and significantly less active against hDHFR.
- These compounds can therefore selectively affect (e.g., kill, inhibit growth/proliferation of) microorganisms through the inhibition of bDHFR with reduction or elimination of substantial side effects to the subject (e.g., human, animal, mammal), including those associated (in whole or in part) with inhibition of hDHFR.
- the invention also relates to the specific compounds exemplified herein.
- one embodiment of the invention is any compound specifically delineated herein, including the exemplary compounds listed below: TABLE 1 Compounds and their IDs ID STRUCTURE 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66
- the following table of compounds of one aspect of the invention have potent antimicrobial activity against S. aureus bacteria and are anticipated to have physical-chemical properties similar to those of orally absorbed and bioavailable drugs and drug-like compounds. Antibacterial activity for a variety of bacterial species are shown ( S. aureus, S. pneumoniae, E. faecalis, M. catarrhalis , and H. influenzae ).
- the yeast cell ( S. cerevisiae ) in this panel of organisms is an indicator of potential cytotoxicity in mammalian cells. All analogs assayed showed “toxicity” at higher concentrations than 32 ug/mL.
- the compounds of this invention may be synthesized using conventional techniques. Advantageously, these compounds are conveniently synthesized from readily available starting materials. In general, the compounds of the formulae described herein are conveniently obtained via methods illustrated in the schemes and the Examples herein.
- one embodiment relates to a method of making a compound of the formulae described herein, comprising synthesizing any one or more intermediates illustrated in the synthetic schemes herein and then converting that intermediate(s) to a compound of the formulae described herein.
- Another embodiment relates to a method of making a compound of the formulae described herein, comprising synthesizing any one or more intermediates illustrated in the examples herein and then converting that intermediate(s) to a compound of the formulae described herein.
- Another embodiment relates to a method of making a compound of the formulae described herein, comprising synthesizing any one or more intermediates illustrated in the synthetic schemes herein and then converting that intermediate(s) to a compound of the formulae described herein utilizing one or more of the chemical reactions described in the synthetic schemes or examples herein.
- Nucleophilic agents are known in the art and are described in the chemical texts and treatises referred to herein.
- the chemicals used in the aforementioned methods may include, for example, solvents, reagents, catalysts, protecting group and deprotecting group reagents and the like.
- the methods described above may also additionally comprise steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compound of the formulae described herein.
- Pyrimidopyrimdine compounds of the invention can be prepared using a variety of synthetic strategies.
- the pyrimidopyrimidine ring system can be synthesized in a multi-step reaction sequence starting from an appropriately substituted amidine (R7-C ⁇ NHNH2) and an R5-substituted alkoxylmethylenemalonitrile.
- the resulting cyanoaminopyrimidine can be condensed with guanidine to form the pyrimidopyrimine ring system.
- R7 in the cyanoaminopyrimidine is either —Cl, —Br, —S-lower alkyl
- these leaving groups can be substituted with substituted nitrogen or oxygen nucleophiles to provide R7-N(or O)-substituted alkyl or aryl intermediates.
- These intermediates can be cyclized to their corresponding pyrimidopyrimidines with appropriately substituted at the 7-position.
- Another method to synthesize 7-aminosubstituted pyrimidopyrimidines is through the nucleophilic attack of amines on 6-amino-2-bromopyrimidine-5-carbonitrile (chloro or thiomethyl, or thioethyl can also be used as leaving groups at the 2-position), and subsequent cyclization of the resulting, appropriately substituted cyanoaminopyrimidine with guanidine.
- the attacking, appropriately substituted nucleophilic amine is not commercially available, then it can be prepared using standard methods in organic chemistry.
- One such standard method used in preparing compounds in this application is by reductive-amination.
- Compounds of the invention can also be prepared by the aromatic nucleophilic displacement of leaving groups on the 7-position of 2,4-diaminopyrimidopyrimidine.
- These leaving groups [LG] include, but are not limited to: —Cl, —Br, —SCH 3 , —SC 2 H 5 , and —N(CH3) 3 .
- the nucleophile used in the displacement reaction can be —N-alkyl, —N-aryl, or substituted alkyl or aryl amines, or —O-alkyl, —O-aryl, or substituted alcohols or phenols.
- either 6- or 7-substituted pterin analogs can be prepared by the reaction of an activated reagent such as 6- or 7-chloromethyl pterin with nucleophiles such as amines, and by various other methods described in the literature other functional groups at the 6- and 7-position of pterin such as bromomethyl, iodomethyl, hydroxymethyl, activated hydrodroxymethyl, carbonyl, activated carbonyl, hydroxy, chloro, bromo, or methyl can be used as synthetic reagents for the preparation of 6- or 7-substitued analogs.
- an activated reagent such as 6- or 7-chloromethyl pterin
- nucleophiles such as amines
- the above general reaction pathway can be used to synthesize a broad range of 7-substituted pteridine analogs.
- 7-chloromethyl and an appropriate amine are reacted in an appropriate solvent such as DMF or 2-methoxyethanol for as long as needed as determined by analysis of the reaction mixture by HPLC, TLC, or NMR.
- the solvent is then removed and the product purified by an appropriate method, usually in the form of precipitation, recrystallization, re-precipitation of the salt by base, or through chromatography.
- 2,4-Diamino pteridinyl substituted at C-6 with a leaving group-containing alkyl in a suitable solvent is coupled with an amine, aniline, phenol, or alkoxide, which functions as a nucleophile, in the presence of a suitable base.
- a leaving group is a chemical group that can be detached from a molecule during a reaction.
- the leaving group may be of an ionic form after detachment from the original molecule (e.g., —OH, —SMe, —OAc, —OTosyl, Cl—, Br—, I—) or can be of neutral form (e.g., H 2 O, HOAc).
- the resulting product is then isolated and purified using standard and known techniques.
- a diaminopyrimidinyl pyridinyl compound can be treated using similar methodology to prepare a compound herein in which A is CH or C-lower alkyl.
- the compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.
- the compounds of this invention may also be represented in multiple tautomeric forms (see illustration), in such instances, the invention expressly includes all tautomeric forms of the compounds described herein (e.g., alkylation of a ring system may result in alkyation at multiple sites, the invention expressly includes all such reaction products). All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.
- Substituents on ring moieties may be attached to specific atoms, whereby they are intended to be fixed to that atom, or they may be drawn unattached to a specific atom (see below), whereby they are intended to be attached at any available atom that is not already substituted by an atom other than H (hydrogen).
- ring moieties e.g., phenyl, thienyl, etc.
- the compounds of this invention including the compounds of formulae described herein, are defined to include pharmaceutically acceptable derivatives or prodrugs thereof.
- a “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention.
- Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.
- Preferred prodrugs include derivatives where a group which enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein.
- the compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties.
- modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases.
- suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate,
- Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl) 4 + salts.
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium
- ammonium e.g., ammonium
- N-(alkyl) 4 + salts e.g., sodium
- alkali metal e.g., sodium
- alkaline earth metal e.g., magnesium
- ammonium e.g., sodium
- N-(alkyl) 4 + salts e.g., sodium
- the compounds can be screened for antibacterial activity using standard methods.
- broth microdilution techniques are used to measure in vitro activity of the compounds against a given bacterial culture, to yield minimum inhibitory concentration (MIC) data.
- MIC minimum inhibitory concentration
- Table 2 TABLE 2 MIC ( ⁇ g/mL) of some compounds for various bacteria (data given in mg/l n.t.: not tested).
- ID coli aureus faecalis pneumoniae catarrhalis influenzae aeruginosa cerevisiae 1 >64 16-64 16-64 ⁇ 2 2-8 2-8 >64 >64 3 >64 2-8 2-8 2-8 2-8 >64 >64 4 >64 16-64 2-8 2-8 16-64 2-8 >64 >64 5 >64 16-64 2-8 2-8 2-8 >64 >64 6 >64 2-8 2-8 2-8 2-8 >64 >64 >64 7 >64 ⁇ 2 ⁇ 2 ⁇ 2 ⁇ 2 >64 >64 8 >64 2-8 2-8 2-8 2-8 2-8 2-8 >64 >64 9 >64 2-8 ⁇ 2 ⁇ 2 2-8 ⁇ 2 >64 >64 10 >64 2-8 ⁇ 2 2-8 ⁇ 2 16-64 >64 16-64 11 >64 ⁇ 2 ⁇ 2 ⁇ 2 >64 >64 >64 12 >64 >64 >64 n.t.
- Bacterial inocula were prepared from overnight culture (i.e., one fresh colony from agar plate in 5 ml MHB; H. influenzae was grown in MHB with the addition of yeast extract, haematin, and NAD), centrifuged 2 ⁇ 5 min/3000 rpm (for S. pneumoniae and H. influenzae, 2 ⁇ 10 min/3000 rpm), and dispensed in 5 ml of fresh MHB each time, such that the bacterial suspension is diluted to obtain 100 colony forming units (cfu) in a microplate well (100 ⁇ l total volume).
- Microplate wells were filled with two-fold dilutions of test compound (50 ⁇ l), starting with 64 ⁇ g/ml. Wells were then filled with 50 ⁇ l of bacterial inoculum (final volume: 100 ⁇ l/well). The plates were incubated at 37° C. for 18-24 hours ( S. pneumoniae was grown in a CO 2 -enriched atmosphere).
- E. coli DHFR was kindly provided by Eric Brown of MacMaster University.
- the human DHFR cDNA was cloned by PCR from the Human Universal Quick-cloneTM cDNA purchased from Clontech. PCR primers were designed from the human sequence deposited in GenBank (1) under Accession number XM — 003991. The primer sequences are as follows and result in the amplification of a 186 amino acid hDHFR coding region:
- the PCR fragment was digested with restriction enzymes NdeI and HindIII, and then ligated into a derivative of the pKK223-3 expression vector (Amersham Pharmacia).
- the final expression vector (pFW96.2) was transformed into E. coli Top10 F 40 and hDHFR protein was induced by the addition of 1 mM IPTG followed by incubation at 37° C. for 4 hrs.
- Recombinant human DHFR was purified based on a previously published procedure (2).
- Dihydrofolic acid and NADPH were purchased from Sigma. Enzyme assays were adapted for microtitre format from a previously published procedure (2, 3). All assays were performed in a 250 ⁇ l volume in 96-well microtitre plates. Typical assays consisted of 20 nM DHFR (human or E. coli ), 100 ⁇ M NADPH, and 50 ⁇ M dihydrofolic acid in 100 mM HEPES pH 8, 10 mM KCl, and 10 mM MgCl 2 . The assay was monitored spectrophotometrically for the conversion of NADPH to NADP+, which results in a decrease in absorbance at 340 nm. The extinction coefficient for the reaction at 340 nm (12,300 M ⁇ 1 cm ⁇ 1 ) (4) was used to convert absorbance to concentration of product.
- the compounds of the invention are generally more potent for the inhibition of the bacterial DHFR (bDHFR) enzyme over human DHFR (hDHFR) enzyme.
- This selectivity of inhibition is a useful property in antibacterial drugs.
- the antibacterial drug Trimethoprim is an example. Trimethprim inhibits bacterial DHFR at ⁇ 0.002 uM; Trimethoprim is essentially ineffective at inhibiting human DHFR enzymes. Inhibition of human DHFR causes profound side-effects in human patients. Compounds with a high human versus bacterial DHFR inhibition ratio can be considered “safer” with regards to their primary mechanism of side-effect; i.e., the inhibition of hDHFR.
- Methotrexate is a drug used in the treatment of cancer. Its primary mechanism of action is through the inhibition of hDHFR enzymes present in cancerous cells. Many side-effects of this form of cancer-chemotherapy are the result of inhibition of hDHFR.
- Drugs like trimetrexate are antimicrobial agents (6-substituted-quinazoline) that have significant hDHFR inhibition. It is necessary to administer/co-administer what is termed a “rescue” drug, e.g., leukovorin, to the patient to combat the powerful, deadly side-effects of hDHFR inhibition.
- a compound of a formulae herein is one that inhibits bacterial DHFR at a much lower dose (high potency) than that which shows inhibition of hDHFR enzymes, or has a therapeutic index (i.e., the ratio of HDHFR Ki/bDHFR Ki) greater than 10 (e.g., >50, >100, >1000, >10,000, >20,000, >25,000).
- the compounds can also be tested for antibacterial efficacy in laboratory animals. These in vivo studies include, but are not limited to, systemic and topical models of infection, urinary tract infection models, helicobacter infections including ulcers of the gastrointestinal tract, sepsis, antibiotic mediated colitis and wound care.
- the compounds of the invention can also be evaluated in animals to assess their pharmacokinetic profiles, such as oral bioavailability, oral absorption, chemical half-life, identification of metabolites, serum levels at various times, and rate of excretion, for example.
- Azithromycin is dissolved in 0.5% methocel in saline solution and administered orally.
- Test compounds are micronized with mortar and pestle and then dissolved in methocel saline solution with 3% of DMF.
- the first dose is administered 30 minutes after infection, with following doses every 12 hours for 3 days.
- the compounds claimed in this invention can be used therapeutically or prophylactically for treatment or prevention of bacterial infections and/or diseases.
- the invention also relates to methods of disrupting the internal regulation of microbial growth or respiration, in a subject, comprising the step of administering to said subject a compound of any of the formulae described herein or a composition comprising a compound of any of the formulae described herein.
- the invention relates to a method of inhibiting microbial or bacterial activity in a subject comprising the step of administering a compound to the subject, or a composition comprising a compound, of any one of the formulae described herein.
- the subject is a human being or animal.
- this invention relates to a method of treating disease or disease symptoms in a subject comprising the step of administering to said subject a compound, or a composition comprising a compound, of any of the formulae described herein.
- the subject is a human being or animal.
- Infections and infectious diseases are caused from a variety of microorganisms.
- the compounds of the invention may find use in the medical treatment of infectious diseases from bacterial sources.
- Upper and lower respiratory tract infections include, but are not limited to: bronchitis, sinusitis, pneumonia, sore throat, chronic streptococcal infections, diphtheria, acute epiglottitis, influenza, chronic bronchitis, middle ear infections (otitis media), pneumonia, bronchopneumonia, Legionnaire's disease, atypical pneumonia, whooping cough, and tuberculosis.
- Bacterial microorganisms causing respiratory tract infections include but are not limited to: S.pyogenes, S.pneumoniae, S.aureus, H.influenzae, M.catarrhalis, N.meningitidis, B. pertussis ,, Enterobacteriaceae, Anerobes, Nocardia, Pseudomonas, C. psittaci , and C. diphtheriae.
- Urinary tract infections include, but are not limited to: urethritis, cystitis, pyelonephritis (kidney infection), asymptomatic bacteruria, interstitial cystitis, acute urethral syndrome, and recurrent urinary tract infections.
- Bacterial microorganisms causing urinary tract infections include but are not limited to: E. coli , Proteus, Providentia, Pseudomonas, Klebsiella, Enterobacter, Serratia, Coag. neg. Staphylococci, Enterococci, and C. trachomatis.
- Skin and wound infections include, but are not limited to: erythrasma, panaritium, impetigo, folliculitis, erysipelas, cellulitis, and necrotizing fasciitis.
- Bacterial microorganisms causing skin and wound infections include but are not limited to: Streptococci, Staphylococci, P. aeruginosa, P. acnes, Clostridia, anaerobes , and B. fragilis.
- Bacterial microorganisms causing systemic infections include but are not limited to: Streptococci, Staphylococci, Enterobacteriaceae, Pseudomonas, Bacteroides sp., Neisseria, H. influenzae , Brucella, Listeria, and S. typhi.
- Sexually transmitted diseases of bacterial origin include, but are not limited to: adnexitis, cervicitis, chanchroid, urethritis, balanitis, gonorrhea, lymphogranuloma venereum, syphilis, and granuloma inguinale.
- Bacterial microorganisms causing sexually transmitted infections include but are not limited to: Chlamydia, N. gonorrhoeae, U. urealyticum, T. pallidium, G. vaginalis, H. ducreyi, C. granulomatis , Streptococci, Staphylococci, and Enterobacteriae.
- Gastrointestinal infections of bacterial origin include but are not limited to: food borne infections, colitis, enteritis, gastric ulcers, duodenal ulcers, pancreatitis, gall bladder infections, cholera, and thyphus.
- Bacterial microorganisms causing gastrointestinal infections include but are not limited to: H. pylori, C. pylori, C. duodeni, S. typhi, S. paratyphi, V. cholerae , anaerobes, Enterobacteriaceae, Staphylococci, and Streptococci.
- the heterocyclic compounds of the formulae delineated herein can be administered to a patient, for example, in order to treat an infection such as a bacterial infection.
- the heterocyclic compounds can, for example, be administered in a pharmaceutically acceptable carrier such as physiological saline, in combination with other drugs, and/or together with appropriate excipients.
- heterocyclic compounds of the formulae described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.001 to about 100 mg/kg of body weight, preferably dosages between 10 mg and 5000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug.
- the methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect.
- the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
- the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
- a typical preparation will contain from about 5% to about 95% active compound (w/w).
- such preparations contain from about 20% to about 80% active compound.
- a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
- this invention provides methods of treating, preventing, or relieving symptoms of disease in a subject comprising the step of administrating to said subject any of the pharmaceutical compositions and combinations described above.
- the subject is a human.
- such methods may additionally comprise the step of administering to said subject an additional therapeutic agent such as, for example, a sulfa drug or a sulfonamide (e.g., sulfamethoxzole), macrolide antibiotics (e.g., clarithromycin), proton pump inhibitors (e.g., omeprazole), rifamycins (e.g., rifampin), aminoglycosides (e.g., streptomycin, gentamycin,, tobramycin), penicillins (e.g., penicillin G, penicillin V, ticarcillin), ⁇ -lactamase inhibitors, cephalosporins (e.g.,
- Such additional(s) agent may be administered to the subject prior to, concurrently with, or following the administration of the composition having a compound of any of the formulae described herein.
- compositions of this invention comprise a compound of the formulae described herein or a pharmaceutically acceptable salt thereof; an additional agent selected from an anticancer agent, an anti-viral agent, antifungal agent, antibiotic, proton pump inhibitors, and any pharmaceutically acceptable carrier, adjuvant or vehicle.
- additional agent selected from an anticancer agent, an anti-viral agent, antifungal agent, antibiotic, proton pump inhibitors, and any pharmaceutically acceptable carrier, adjuvant or vehicle.
- Alternate compositions of this invention comprise a compound of the formulae described herein or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, adjuvant or vehicle.
- Such compositions may optionally comprise additional therapeutic agents, including, for example an additional agent selected from an anticancer agent, an antiviral agent, antifungal agent, antibiotic, and any pharmaceutically acceptable carrier, adjuvant or vehicle.
- compositions of this invention comprise a compound of the formulae described herein or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, adjuvant or vehicle.
- Such compositions may optionally comprise additional therapeutic agents, including, for example an additional agent selected from an anticancer agent, an antimicrobial agent, an antiviral agent, antifungal agent, proton pump inhibitor, or antibiotic.
- additional therapeutic agents including, for example an additional agent selected from an anticancer agent, an antimicrobial agent, an antiviral agent, antifungal agent, proton pump inhibitor, or antibiotic.
- the compositions delineated herein include the compounds of the formulae delineated herein, as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of microbial or bacterial levels.
- pharmaceutically acceptable carrier or adjuvant refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
- compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- ⁇ -tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes,
- Cyclodextrins such as ⁇ -, ⁇ -, and ⁇ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- ⁇ -cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
- compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection.
- the pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles.
- the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form.
- parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
- the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension.
- This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- suitable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
- These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions.
- surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
- compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.
- carriers which are commonly used include lactose and corn starch.
- Lubricating agents such as magnesium stearate, are also typically added.
- useful diluents include lactose and dried corn starch.
- aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
- compositions of this invention may also be administered in the form of suppositories for rectal administration.
- These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components.
- suitable non-irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
- Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application.
- the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier.
- Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water.
- the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents.
- Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
- the pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.
- compositions of this invention may be administered by nasal aerosol or inhalation.
- Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
- compositions of this invention are useful as sterilizants, antiseptics, adjuvants in wound dressings (e.g., bandages), and adjuvants in wound cleansing methods (swipes, gavage, etc.).
- compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents
- both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
- the additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
- Examples of potential application of combination therapies include compounds of any of the formulae delineated herein and the following: in combination with a macrolide antibiotic and a proton pump inhibitor for the treatment of gastritis and associated diseases caused by Helicobacter pylori ; in combination with antibacterials (e.g., sulfamethoxazole, ciprofloxacin and amoxicillin) for the treatment of urinary tract infections; e.g. in combination with rifamycins for treatment of staphylococcal infections; e.g. in combination with rifamycins, isoniazid, ethambutol, or aminoglycosides for the treatment of mycobacterial infections; e.g.
- antibacterials e.g., sulfamethoxazole, ciprofloxacin and amoxicillin
- urinary tract infections e.g. in combination with rifamycins for treatment of staphylococcal infections
- DHFR inhibitors e.g., trimethoprim, DHFR inhibitors delineated herein.
- Liquid chromatographic data was obtained using a Hewlett-Packard (HP) 1090 Series Liquid Chromatograph coupled to a Diode Array Detector [Restek Allure C18 Column; particle size, 5 ⁇ M; column length, 150 mm; column diameter, 4.6 mm; flow rate, 1 mL/min; Solvent program, from 95% H 2 O (w/0.1% TFA)/5% CH 3 CN (w/0.1% TFA) to 100% CH 3 CN (w/0.1% TFA) in 8 minutes, then held constant for 3 minutes; detection wavelength, 254 nm].
- Mass Spectral data were obtained on either an Agilent 1100 LC/MS or Thermofinigan AQA/Gilson LC/MS system. 1 H- and 13 C-NMR spectra were obtained on a Bruker AC-300 MHz instrument. Medium pressure flash chromatography was performed on an Isco Inc., Combiflash Sg100c system. Thin-layer chromatography was performed using EM Science silica gel 60 F 254 plastic TLC plates. Melting points were determined in open-air capillary tubes in a Meltemp II apparatus. UV light was used for detecting compounds on the TLC plates. Reagents used in reactions were purchased from the Aldrich Chemical Co. (Milwaukee, Wis.), Sigma Chemical Co.
- 6-substituted pterin analogs can be prepared by the reaction of an activated reagent such as 6-chloromethyl pterin with nucleophiles such as amines (e.g., HNR′R′′ can be HNHY or HNR 16 Y).
- nucleophiles such as amines
- Other functional groups at the 6-position of pterin such as bromomethyl, iodomethyl, hydroxymethyl, activated hydroxymethyl, carbonyl (e.g., ketone or aldehyde), activated carbonyl (e.g., ester, amide, or anhydride), hydroxy, chloro, bromo, or methyl can be used as synthetic reagents for the preparation of 6-substitued analogs.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates to novel heterocyclic compounds and to their use in the medical treatment or prophylaxis of bacterial infections, or their use as antiseptics, sterilizants, or disinfectants.
Description
- This application claims the benefit of U.S. Provisional Application No. 60/301,685, filed Jun. 28, 2001, which is hereby incorporated by reference in its entirety.
- This invention relates to novel heterocyclic compounds and to their use, for example, in the prophylaxis and or medical treatment of bacterial infections, and their use as antiseptics, sterilizants, or disinfectants.
- Research efforts in the fight against infection are ever increasing in order to keep pace with the proliferation of resistant microorganisms. Bacteria are continually mutating and evolving in a manner that convey increased resistance to existing therapeutics. This is particularly alarming in hospital settings, where a large proportion of observed pathogens are resistant to one or more standard treatment regimens. Additionally, the increase in the incidence of opportunistic infection in immunocompromised patients has contributed to the heightened urgency for novel therapies against infectious disease and disease symptoms. As a result, there is a very strong need for therapeutic agents that are more potent generally, more effective against resistant strains, and that cause fewer side effects than existing drugs. To address this increasing need, the focus of antimicrobial research includes the study of new agents that work by novel mechanisms, new agents that overcome known resistance profiles, and new or improved agents that act via known mechanisms.
- The invention relates to heterocyclic compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making the compounds and methods for identifying compounds with desired biological activity.
- The invention is based on the discovery that certain heterocyclic compounds have potent antibacterial activity. Thus, this invention relates to novel heterocyclic compounds and to their use in the prophylaxis and/or medical treatment of bacterial infections or as antiseptics, sterilizants, or disinfectants. The invention is further based on the discovery that certain heterocyclic compounds, including in general, substituted pteridinyl, quinazolinyl and pyrimidopyrimidinyl heterocycles, have potent antibacterial activity and are useful in the treatment of a variety of human diseases and microbial infections. As the heterocyclic compounds show selective inhibition of bacterial dihydrofolate reductase (bDHFR) versus human DHFR (hDHFR), the compounds of the invention can be useful in the treatment of microbial infections without human toxicity associated with inhibition of hDHFR.
-
- wherein A is N, CH, or CR15; R14 is —(CH2)n—X—Y, wherein n is 1, 2, 3, 4, 5, or 6; X is O, NH, or NR15; and Y is aryl or heteroaryl, wherein each Y is optionally substituted with 1-4 independent R16. Each R15 is independently lower alkyl; each R16 is independently halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, S(O)2NR17R17, S(O)2R17, C(O)OR18, C(O)NH2, or C(O)NR19R20; each R17 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21; each R18 is in hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21; each R19 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR2R21, S(O)2NR21R21, or S(O)21R21; each R20 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21; and each R21 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, or heteroarylalkoxy.
-
- wherein A is N, CH, or CR15; each R14 is independently —(CH2)n—X—Y, wherein n is 1, 2, 3, 4, 5, or 6; X is O, NH, or NR15; and Y is aryl or heteroaryl, wherein each Y is optionally substituted with 1-4 independent R16. Each R15 is independently lower alkyl; each R16 is independently halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, S(O)2NR17R17, S(O)2R17, C(O)OR18, C(O)NH2, or C(O)NR19R20; each R17 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21; each R18 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21; each R19 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21; each R20 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21; and each R21 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, or heteroarylalkoxy. In one aspect, the compounds (and compositions and methods relating to them) are those wherein each R14 is the same. In another aspect the compounds (and compositions and methods relating to them) are those wherein each R14 is different.
- The term “halo” refers to any radical of fluorine, chlorine, bromine or iodine. The term “alkyl” refers to a hydrocarbon chain that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C1-C10 indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it. The term “lower alkyl” refers to a C1-C8 alkyl chain. The term “alkoxy” refers to an —O-alkyl radical. The term “alkylene” refers to a divalent alkyl (i.e., —R—). The term “alkylenedioxo” refers to a divalent species of the structure —O—R—O—, in which R represents an alkylene. The term “aminoalkyl” refers to an alkyl substituted with an amino. The term “mercapto” refers to an —SH radical. The term “thioalkoxy” refers to an —S-alkyl radical.
- The term “aryl” refers to a 6-carbon monocyclic or 10-carbon bicyclic aromatic ring system wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent. Examples of aryl groups include phenyl, naphthyl and the like. The term “arylalkyl” or the term “aralkyl” refers to alkyl substituted with an aryl. The term “arylalkoxy” refers to an alkoxy substituted with aryl.
- The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic ring system comprising 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, said heteroatoms selected from O, N, or S, wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent. Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like. The term “heteroarylalkyl” or the term “heteroaralkyl” refers to an alkyl substituted with a heteroaryl. The term “heteroarylalkoxy” refers to an alkoxy substituted with heteroaryl.
- A carbon-, nitrogen-, sulfur- halogen- and/or oxygen-containing function group is a substituted or unsubstituted, linear, branched, or cyclic, alkyl, alkenyl, alkynyl, aryl, aralkyl, or alkaryl group, or a derivative of one or more of these groups where heteroatoms are substituted for one or more of the carbon and/or hydrogen atoms (e.g., amino groups, alkylamino groups, hydroxyl and alkoxyl groups, thiol groups, halogens, nitro groups, phenolic groups, or other substituted aromatic or aliphatic groups)).
-
-
- those wherein A is CH or CR15; those wherein each R16 is independently C(O)NR19R20 [each R19 is independently aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and each R20 is independently aminoalkyl, aryl, or arylalkyl; each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21]; those wherein Y is heteroaryl; those wherein n is 1 and X is NH or NR15, and Y is phenyl substituted with one R16, in which R16 is not —COOH; and those wherein n is 1 and X is NH or NR15, and Y is phenyl substituted with 2-4 independent R16.
-
- optionally substituted with 1-4 independent R16, each R16 being halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)OR18, C(O)NH2, or C(O)NR19R20; and those wherein Y is phenyl (optionally substituted with 1-4 independent R16) and A is N.
- Other embodiments include compounds of any of the formulae described herein wherein n is 1, X is O, and A is N; those wherein n is 1, X is O, Y is phenyl, optionally substituted with 1-4 independent R16; those wherein n is 1, X is O, Y is phenyl substituted with 1-4 independent R16; those wherein n is 1, X is NH or NR15 (wherein R15 is CH3), A is N; those wherein n is 1, X is NH or NR15 (wherein R15 is CH3), A is N, Y is phenyl, optionally substituted with 1-4 independent R16; those wherein n is 1, X is NH or NR15 (wherein R15 is CH3), A is N, Y is phenyl; those wherein n is 1, X is NH or NR15 (wherein R15 is CH3), A is N, Y is phenyl, optionally substituted with 1-4 independent R16, wherein each R16 is independently halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)OR18, C(O)NH2, or C(O)NR19R20; those wherein n is 1, X is NH or NR15 (wherein R15 is CH3), A is N, Y is phenyl, optionally substituted with 1-4 independent R16, wherein each R16 is independently C(O)OR18; those herein n is 1, X is NH or NR15 (wherein R15 is CH3), A is N, Y is phenyl, optionally substituted with 1-4 independent R16, wherein each R16 is independently C(O)OR18 and each R18 is H or alkyl; those wherein n is 1, X is NH or NR15 (wherein R15 is CH3), A is N, Y is phenyl, optionally substituted with 1-4 independent R16, wherein each R16 is independently C(O)NR19R20.
-
-
-
-
-
- or any of the compounds in Table 1.
-
- wherein
- A and B are independently selected from the group consisting of N and CR7, wherein R7 is hydrogen or a carbon-, nitrogen-, sulfur- halogen- and/or oxygen-containing function group;
- R1 and R2 are —NR5R6 groups, wherein R5 and R6 are independently hydrogen or carbon-containing functional groups;
- R3 is hydrogen;
- R4 is a carbon-, nitrogen-, sulfur-, halogen-, and/or oxygen-containing functional group,
- provided that,
- if A and B are both nitrogen and R5 and R6 are both hydrogen, then R4 is not —NH2, —N(H)(methyl), —N(H)(butyl), —N(H)(hexyl), —N(H)(phenyl), —N(H)(benzyl), —N(H)(NH2), —N(H)(CH2CH2OH), —N(CH2CH2OH)2, phenyl, N-piperidinyl, or —S(ethyl);
- if A is CH, B is nitrogen, and R5 and R6 are both hydrogen, then R4 is not methyl, isobutyl, phenyl, 4-methylphenyl, 4-chlorophenyl, 4-bromophenyl, 2-(2,5-dimethoxyphenyl)-ethyl, or —CH(OCH3)2; and
- if A and B are both CH groups, then R4 is an amino group other than —NH2, (3,4-dichlorophenyl)methylamino, or (3,4-dichlorophenyl)methyleneimino.
- In other aspeacts, the compounds are those of formula III wherein,
- R5 and R6 are independently hydrogen; and
- A and B are each independently N;
- those of any of the formulae herein wherein,
- R4 is NR7R8;
- those of any of the formulae herein wherein,
- R4 is NR7R8;
- R7 is C1-C6 alkyl substituted with aryl or heteroaryl; and
- R8 is C1-C6 alkyl optionally substituted with alkenyl, hydroxyl, alkoxy, cycloalkyl, or aryl;
- those of any of the formulae herein wherein,
- R7 is C1-C6 alkyl substituted with aryl;
- R8 is C1-C6 alkyl;
- those of any of the formulae herein wherein,
- R7 is C1-C6 alkyl substituted with heteroaryl;
- R8 is C1-C6 alkyl;
- those of any of the formulae herein wherein,
- R7 is C1-C6 alkyl substituted with aryl;
- R8 is C1-C6 alkyl substituted with hydroxyl or alkoxy;
- those of any of the formulae herein wherein
- R4 is NR7R8;
- those of any of the formulae herein wherein
- R4 is NR7R8;
- R7 is C1-C6 alkyl;
- R8 is C1-C6 alkyl substituted with cycloalkyl;
- those of any of the formulae herein wherein,
- R4 is NR7R8;
- R7 is independently C1-C6 alkyl substituted with aryl;
- R8 is independently C1-C6 alkyl substituted with aryl;
- those of any of the formulae herein, wherein
- R7 is hydrogen, alkyl, cycloalkyl, aryl, halogen, thioalkyl, hydroxy, alkoxy, amino, alkyl, or NR5R6; wherein each R5 and R6 on the nitrogen atom independently is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroarylalkyl, or alkylcarbonyl;
- those of any of the formulae herein, wherein
- R7 is C1-C6 alkyl substituted with naphthyl, which is optionally substituted with alkyl, halo, hydroxy, alkoxy, thioalkyl, or amino;
- those of any of the formulae herein, wherein the naphthyl group is substituted at the 2- or 4-position;
- those of any of the formulae herein, wherein
- R8 is methyl or ethyl;
- those of any of the formulae herein, wherein
- R7 is C1-C6 alkyl substituted with benzothienyl, which is optionally substituted with alkyl, halo, hydroxy, alkoxy, thioalkyl, or amino;
- those of any of the formulae herein, wherein R8 is methyl or ethyl.
- Other aspects of this invention relate to a composition having a compound of any of the formulae described herein and a pharmaceutically acceptable carrier; or a compound of any of the formulae described herein, an additional therapeutic agent, and a pharmaceutically acceptable carrier; or a compound of any of the formulae described herein, an additional therapeutic agent, and a pharmaceutically acceptable carrier, wherein the additional therapeutic agent is an antibacterial agent.
- Yet another aspect of this invention relates to a method of treating a subject (e.g., mammal) infected with one or more bacteria (including, but not limited to urinary tract infections, systemic and topical infections, sepsis, antibiotic mediated colitis, ulcers of the gastrointestinal tract, topical disinfectant, antiseptic, sterilizant, wound care, and surgical cleansing). The method includes administering to the subject (including a subject identified as in need of such treatment) an effective amount of a compound described herein, or a composition described herein to produce such effect.
- The compounds and compositions herein are also useful as antiparasitic agents. Another aspect of this invention relates to a method of treating a subject (e.g., a mammal) infected with one or more parasites. The method includes administering to the subject (including a subject identified as in need of such treatment) an effective amount of a compound described herein, or a composition described herein to treat parasites, or disease, infection, or symptoms thereof.
- The invention also relates to a method of making a compound described herein. The method includes taking a 2,4-diamino pteridinyl (or a 2,4-diaminopyrimidopyrimidinyl) compound and reacting it with one or more chemical reagents in one or more steps to produce a compound described herein. Alternatively, the method includes taking any one of the intermediate compounds described herein and reacting it with one or chemical reagents in one or more steps to produce a compound described herein.
- The invention further relates to a product (i.e., a compound of any of the formulae) made by the method described above.
- Also within the scope of this invention are a method for identifying a compound having antibacterial activity which includes: a) assessing the structure of a compound of a formula herein; b) procuring a derivative compound of the compound from step a); and c) assessing the antibacterial activity of the derivative compound; and a method for identifying a compound having antibacterial activity which includes: a) taking a candidate compound; b) assessing the binding affinity of the candidate compound in a model of the DHFR (e.g., bDHFR, hDHFR) enzyme; and c) assessing the antibacterial activity of the candidate compound. Assessing antibacterial activity can be performed by a variety of procedures known in the art, including those delineated herein.
- A compound that can inhibit bacterial DHFR selectively over human DHFR can provide an advantageous treatment option for bacterial disease or disease symptoms. 6-substituted pteridines have been described in the literature as potent inhibitors of either human DHFR (e.g. methotrexate, used as anti-cancer agent) or bacterial DHFR (e.g. Trimetrexate used for treatment of bacterial and parastic infections), Existing treatments with compounds such as trimetrexate have severe side effects and toxicities associated with inhibition of DHFR. The compounds in this invention are potent bDHFR inhibitors and significantly less active against hDHFR. These compounds can therefore selectively affect (e.g., kill, inhibit growth/proliferation of) microorganisms through the inhibition of bDHFR with reduction or elimination of substantial side effects to the subject (e.g., human, animal, mammal), including those associated (in whole or in part) with inhibition of hDHFR.
- Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term “stable”, as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject or antiseptic, wound dressing impregnation, sterilizant, or disinfectant applications).
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
- Specific features and advantages of the invention will be apparent from the following detailed description, and from the claims.
- The invention also relates to the specific compounds exemplified herein. Thus one embodiment of the invention is any compound specifically delineated herein, including the exemplary compounds listed below:
TABLE 1 Compounds and their IDs ID STRUCTURE 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 - The following table of compounds of one aspect of the invention have potent antimicrobial activity againstS. aureus bacteria and are anticipated to have physical-chemical properties similar to those of orally absorbed and bioavailable drugs and drug-like compounds. Antibacterial activity for a variety of bacterial species are shown (S. aureus, S. pneumoniae, E. faecalis, M. catarrhalis, and H. influenzae). The yeast cell (S. cerevisiae) in this panel of organisms is an indicator of potential cytotoxicity in mammalian cells. All analogs assayed showed “toxicity” at higher concentrations than 32 ug/mL.
- The following table of compounds of one aspect of the invention have potent antimicrobial activity againstS. aureus bacteria and are anticipated to have physical-chemical properties similar to those of orally absorbed and bioavailable drugs and drug-like compounds. MIC's are given in mg/ml
Table of representative compounds of the invention bDHFR S. aureus Corporate ID Ki/(μM) avg (μg/ml) avg 20 0.062 0.5 21 0.082 <0.125 22 0.002 <0.125 23 0.027 1 24 0.015 0.25 25 0.004 0.25 26 0.02 1 27 0.008 0.5 28 0.02 <0.125 29 0.02 <0.125 30 0.028 <0.125 31 0.024 1 32 0.011 0.5 33 0.012 0.015 34 0.014 1 35 0.037 0.5 36 0.005 <0.125 37 0.003 <0.125 38 0.06 0.5 39 0.015 0.25 40 0.004 <0.125 41 0.037 <0.125 42 0.004 <0.125 43 0.004 <0.125 44 0.004 <0.125 45 0.008 2 46 0.093 2 47 0.023 2 48 0.007 2 49 0.02 2 50 0.004 2 51 0.022 2 52 0.022 2 53 0.03 2 54 0.01 2 55 0.019 2 56 0.093 2 57 0.011 2 58 0.015 2 59 0.005 2 60 0.029 2 61 0.013 2 bDHFR S. aureus ID# (nM) Structure MIC 33 12 <0.125 62 802 <0.125 25 <4 0.5 29 <20 0.125 36 5 1 30 24 0.13 21 82 0.25 63 104 0.5 64 385 0.125 ID# S. pneumoniae E. faecalis M. catarrhalis H. influenzae S. cerevisiae MIC MIC MIC MIC MIC 33 .125 1.32 1 8 >64 62 2 >4 4 64 32 25 1 32 4 16 >64 29 0.5 16 1.2 64 64 36 1.8 32 0.5, 1 16 >64 30 2 8 2 64 64 21 0.125 0.015 1 1 >64 63 0.25 0.25 0.25 32 64 64 0.125 0.125 0.125 64 >64 - The compounds of this invention may be synthesized using conventional techniques. Advantageously, these compounds are conveniently synthesized from readily available starting materials. In general, the compounds of the formulae described herein are conveniently obtained via methods illustrated in the schemes and the Examples herein.
- Thus, one embodiment relates to a method of making a compound of the formulae described herein, comprising synthesizing any one or more intermediates illustrated in the synthetic schemes herein and then converting that intermediate(s) to a compound of the formulae described herein. Another embodiment relates to a method of making a compound of the formulae described herein, comprising synthesizing any one or more intermediates illustrated in the examples herein and then converting that intermediate(s) to a compound of the formulae described herein. Another embodiment relates to a method of making a compound of the formulae described herein, comprising synthesizing any one or more intermediates illustrated in the synthetic schemes herein and then converting that intermediate(s) to a compound of the formulae described herein utilizing one or more of the chemical reactions described in the synthetic schemes or examples herein. Nucleophilic agents are known in the art and are described in the chemical texts and treatises referred to herein. The chemicals used in the aforementioned methods may include, for example, solvents, reagents, catalysts, protecting group and deprotecting group reagents and the like. The methods described above may also additionally comprise steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compound of the formulae described herein.
- As can be appreciated by the skilled artisan, the synthetic schemes herein are not intended to comprise a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized. Further methods will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock,Comprehensive Organic Transformations, VCH Publishers (1989); T. W. Greene and P. G. M. Wuts, Protective Groups in Organic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions thereof.
- Discussion of General Synthetic Methodologies Used in the Preparation of Analogs.
- In general, compounds of the invention described herein can be prepared by utilizing standard methods known to those skilled in the art of organic synthesis and using standard methods and techniques described in the literature.
-
- Pyrimidopyrimdine compounds of the invention can be prepared using a variety of synthetic strategies. The pyrimidopyrimidine ring system can be synthesized in a multi-step reaction sequence starting from an appropriately substituted amidine (R7-C═NHNH2) and an R5-substituted alkoxylmethylenemalonitrile. The resulting cyanoaminopyrimidine can be condensed with guanidine to form the pyrimidopyrimine ring system. In the case where R7 in the cyanoaminopyrimidine is either —Cl, —Br, —S-lower alkyl, these leaving groups can be substituted with substituted nitrogen or oxygen nucleophiles to provide R7-N(or O)-substituted alkyl or aryl intermediates. These intermediates can be cyclized to their corresponding pyrimidopyrimidines with appropriately substituted at the 7-position.
- Another method to synthesize 7-aminosubstituted pyrimidopyrimidines is through the nucleophilic attack of amines on 6-amino-2-bromopyrimidine-5-carbonitrile (chloro or thiomethyl, or thioethyl can also be used as leaving groups at the 2-position), and subsequent cyclization of the resulting, appropriately substituted cyanoaminopyrimidine with guanidine.
-
- In this well-known procedure, an aldehyde or ketone is condensed with an appropriately substituted amine in the presence of a mild reducing agent such as sodium cyanoborohydride or zinc cyanoborohydride.
-
- Compounds of the invention can also be prepared by the aromatic nucleophilic displacement of leaving groups on the 7-position of 2,4-diaminopyrimidopyrimidine. These leaving groups [LG] include, but are not limited to: —Cl, —Br, —SCH3, —SC2H5, and —N(CH3)3. The nucleophile used in the displacement reaction can be —N-alkyl, —N-aryl, or substituted alkyl or aryl amines, or —O-alkyl, —O-aryl, or substituted alcohols or phenols.
- Synthesis of Pterin Analogs
- In general either 6- or 7-substituted pterin analogs can be prepared by the reaction of an activated reagent such as 6- or 7-chloromethyl pterin with nucleophiles such as amines, and by various other methods described in the literature other functional groups at the 6- and 7-position of pterin such as bromomethyl, iodomethyl, hydroxymethyl, activated hydrodroxymethyl, carbonyl, activated carbonyl, hydroxy, chloro, bromo, or methyl can be used as synthetic reagents for the preparation of 6- or 7-substitued analogs.
- The above general reaction pathway can be used to synthesize a broad range of 7-substituted pteridine analogs. In a general procedure, 7-chloromethyl and an appropriate amine are reacted in an appropriate solvent such as DMF or 2-methoxyethanol for as long as needed as determined by analysis of the reaction mixture by HPLC, TLC, or NMR. The solvent is then removed and the product purified by an appropriate method, usually in the form of precipitation, recrystallization, re-precipitation of the salt by base, or through chromatography.
- 2,4-Diamino pteridinyl substituted at C-6 with a leaving group-containing alkyl in a suitable solvent is coupled with an amine, aniline, phenol, or alkoxide, which functions as a nucleophile, in the presence of a suitable base. (See the reaction scheme below.) A leaving group is a chemical group that can be detached from a molecule during a reaction. The leaving group may be of an ionic form after detachment from the original molecule (e.g., —OH, —SMe, —OAc, —OTosyl, Cl—, Br—, I—) or can be of neutral form (e.g., H2O, HOAc). The resulting product is then isolated and purified using standard and known techniques.
- Similarly, a diaminopyrimidinyl pyridinyl compound can be treated using similar methodology to prepare a compound herein in which A is CH or C-lower alkyl.
- The compounds of this invention may contain one or more asymmetric centers and thus occur as racemates and racemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention. The compounds of this invention may also be represented in multiple tautomeric forms (see illustration), in such instances, the invention expressly includes all tautomeric forms of the compounds described herein (e.g., alkylation of a ring system may result in alkyation at multiple sites, the invention expressly includes all such reaction products). All such isomeric forms of such compounds are expressly included in the present invention. All crystal forms of the compounds described herein are expressly included in the present invention.
- Substituents on ring moieties (e.g., phenyl, thienyl, etc.) may be attached to specific atoms, whereby they are intended to be fixed to that atom, or they may be drawn unattached to a specific atom (see below), whereby they are intended to be attached at any available atom that is not already substituted by an atom other than H (hydrogen). For example, a structure drawn as:
- is intended to encompass all of (but is not limited to) the following structures:
- All references cited herein, whether in print, electronic, computer readable storage media or other form, are expressly incorporated by reference in their entirety, including but not limited to, abstracts, articles, journals, publications, texts, treatises, internet web sites, databases, patents, and patent publications.
- Formulations, Compositions, and Prodrugs
- As used herein, the compounds of this invention, including the compounds of formulae described herein, are defined to include pharmaceutically acceptable derivatives or prodrugs thereof. A “pharmaceutically acceptable derivative or prodrug” means any pharmaceutically acceptable salt, ester, salt of an ester, or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing (directly or indirectly) a compound of this invention. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Preferred prodrugs include derivatives where a group which enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein.
- The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
- Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts. Salts derived from appropriate bases include alkali metal (e.g., sodium), alkaline earth metal (e.g., magnesium), ammonium and N-(alkyl)4 + salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.
- In vitro Assays for Antibacterial Activity
- The compounds can be screened for antibacterial activity using standard methods.
- In one example, illustrated below, broth microdilution techniques are used to measure in vitro activity of the compounds against a given bacterial culture, to yield minimum inhibitory concentration (MIC) data. The MICs of some representative compounds are provided in Table 2 below.
TABLE 2 MIC (μg/mL) of some compounds for various bacteria (data given in mg/l n.t.: not tested). Compound E. S. E. S. M. H. P. S. ID coli aureus faecalis pneumoniae catarrhalis influenzae aeruginosa cerevisiae 1 >64 16-64 16-64 <2 2-8 2-8 >64 >64 3 >64 2-8 2-8 2-8 2-8 2-8 >64 >64 4 >64 16-64 2-8 2-8 16-64 2-8 >64 >64 5 >64 16-64 2-8 2-8 2-8 2-8 >64 >64 6 >64 2-8 2-8 2-8 2-8 2-8 >64 >64 7 >64 <2 <2 <2 <2 <2 >64 >64 8 >64 2-8 2-8 2-8 2-8 2-8 >64 >64 9 >64 2-8 <2 <2 2-8 <2 >64 >64 10 >64 2-8 <2 2-8 <2 16-64 >64 16-64 11 >64 <2 <2 <2 <2 >64 >64 >64 12 >64 >64 n.t. <2 16-64 2-8 >64 >64 14 >64 <2 <2 <2 <2 <2 >64 >64 15 >64 <2 <2 <2 <2 <2 >64 2-8 16 >64 <2 <2 <2 <2 >64 >64 >64 17 >64 <2 <2 <2 <2 <2 >64 >64 - Microdilution Antimicrobial Susceptibility Test Assay
- Stock solutions of tested compounds were prepared in N,N-dimethylformamide (DMF) at a concentration of 5 mg/mL. Working solutions of the tested compounds were then prepared from the stock solutions, in Mueller-Hinton broth (MHB) with a starting concentration of 64 μg/mL.
- Bacterial inocula were prepared from overnight culture (i.e., one fresh colony from agar plate in 5 ml MHB;H. influenzae was grown in MHB with the addition of yeast extract, haematin, and NAD), centrifuged 2×5 min/3000 rpm (for S. pneumoniae and H. influenzae, 2×10 min/3000 rpm), and dispensed in 5 ml of fresh MHB each time, such that the bacterial suspension is diluted to obtain 100 colony forming units (cfu) in a microplate well (100 μl total volume).
- Microplate wells were filled with two-fold dilutions of test compound (50 μl), starting with 64 μg/ml. Wells were then filled with 50 μl of bacterial inoculum (final volume: 100 μl/well). The plates were incubated at 37° C. for 18-24 hours (S. pneumoniae was grown in a CO2-enriched atmosphere).
- The optical density of each well at 590 nm (OD590) was then measured with a TECAN SpectroFluor Plus®, and minimum inhibitory concentration (MIC) was defined as the concentration that showed 90% inhibition of growth.
- Biochemical Assays to Determine Activity Against Bacterial and Human DHFR
- Materials and Methods:
- Human and Bacterial DHFR:E. coli DHFR was kindly provided by Eric Brown of MacMaster University.
- Cloning, Expression, Purification of Human DHFR
- The human DHFR cDNA was cloned by PCR from the Human Universal Quick-clone™ cDNA purchased from Clontech. PCR primers were designed from the human sequence deposited in GenBank (1) under Accession number XM—003991. The primer sequences are as follows and result in the amplification of a 186 amino acid hDHFR coding region:
- oAlt-92 (5′) PCR primer: gatcgatcgatccatatggttggttcgctaaactgc
- oAlt-93 (3′) PCR primer: gatcgatcaagcttcattaatcattcttctcatatacttc
- The PCR fragment was digested with restriction enzymes NdeI and HindIII, and then ligated into a derivative of the pKK223-3 expression vector (Amersham Pharmacia). The final expression vector (pFW96.2) was transformed intoE. coli Top10 F40 and hDHFR protein was induced by the addition of 1 mM IPTG followed by incubation at 37° C. for 4 hrs. Recombinant human DHFR was purified based on a previously published procedure (2).
- Enzyme Assays
- Dihydrofolic acid and NADPH were purchased from Sigma. Enzyme assays were adapted for microtitre format from a previously published procedure (2, 3). All assays were performed in a 250 μl volume in 96-well microtitre plates. Typical assays consisted of 20 nM DHFR (human orE. coli), 100 μM NADPH, and 50 μM dihydrofolic acid in 100 mM HEPES pH 8, 10 mM KCl, and 10 mM MgCl2. The assay was monitored spectrophotometrically for the conversion of NADPH to NADP+, which results in a decrease in absorbance at 340 nm. The extinction coefficient for the reaction at 340 nm (12,300 M−1 cm−1) (4) was used to convert absorbance to concentration of product.
- K1 Determinations
- Compounds were serially diluted in DMSO to concentration ranges from 25 mM to 1 μM. Five microliters of inhibitor compound in DMSO was added to 120 μl of enzyme solution (40 nM DHFR and 200 μM NADPH). The reaction was initiated by the addition of 125 μl of 100 μM dihydrofolic acid. The final concentrations in the assay were 20 nM DHFR, 100 μM NADPH, 50 μM dihydrofolic acid, and a range of 500 μM to 20 nM inhibitor compound. The final DMSO concentration was 2% of the total volume. Reactions were monitored as described above.
- Observed rates (nM/sec) were plotted versus inhibitor concentration on a log scale and K1 values were determined by fitting the resulting curves to the following equation:
- V=(V max [S])/(K m(1+I/K i)+[S]), where S=dihydrofolate, Km=Michaelis constant for dihydrofolate, I=inhibitor concentration.
- The compounds of the invention are generally more potent for the inhibition of the bacterial DHFR (bDHFR) enzyme over human DHFR (hDHFR) enzyme. This selectivity of inhibition is a useful property in antibacterial drugs. The antibacterial drug Trimethoprim is an example. Trimethprim inhibits bacterial DHFR at <0.002 uM; Trimethoprim is essentially ineffective at inhibiting human DHFR enzymes. Inhibition of human DHFR causes profound side-effects in human patients. Compounds with a high human versus bacterial DHFR inhibition ratio can be considered “safer” with regards to their primary mechanism of side-effect; i.e., the inhibition of hDHFR. Methotrexate is a drug used in the treatment of cancer. Its primary mechanism of action is through the inhibition of hDHFR enzymes present in cancerous cells. Many side-effects of this form of cancer-chemotherapy are the result of inhibition of hDHFR. Drugs like trimetrexate (not shown) are antimicrobial agents (6-substituted-quinazoline) that have significant hDHFR inhibition. It is necessary to administer/co-administer what is termed a “rescue” drug, e.g., leukovorin, to the patient to combat the powerful, deadly side-effects of hDHFR inhibition. Thus in one embodiment, a compound of a formulae herein is one that inhibits bacterial DHFR at a much lower dose (high potency) than that which shows inhibition of hDHFR enzymes, or has a therapeutic index (i.e., the ratio of HDHFR Ki/bDHFR Ki) greater than 10 (e.g., >50, >100, >1000, >10,000, >20,000, >25,000).
- A comparison of bacterial versus human DHFR Ki values of representative compounds herein are summarized below in Table 3 below. The high selectivity of the compounds of the invention for bacterial over human DHFR inhibitions indicates that these analogs may have a high therapeutic index with respect to the ratio of efficacy (antimicrobial activity) in comparison with toxicity (human side-effects associated with hDHFR inhibition).
TABLE 3 Comparison of bacterial versus human DHFR Ki values (nM) of representative compounds Compound ID bDHFR Ki hDHFR 1 <100 500-999 2 100-499 1000-4999 3 <100 1000-4999 4 <100 500-999 5 <100 500-999 6 1000-4999 >5000 7 100-499 >5000 8 1000-4999 >5000 9 100-499 >5000 10 100-499 >5000 11 500-999 >5000 12 100-499 1000-4999 13 500-999 >5000 14 <100 >5000 15 100-499 >5000 16 <100 >5000 17 <100 n.t. 21 <100 >5000 22 <2 >75,000 66 <1000 >500,000 - In vivo Assays for Antibacterial Activity
- The compounds can also be tested for antibacterial efficacy in laboratory animals. These in vivo studies include, but are not limited to, systemic and topical models of infection, urinary tract infection models, helicobacter infections including ulcers of the gastrointestinal tract, sepsis, antibiotic mediated colitis and wound care. The compounds of the invention can also be evaluated in animals to assess their pharmacokinetic profiles, such as oral bioavailability, oral absorption, chemical half-life, identification of metabolites, serum levels at various times, and rate of excretion, for example.
- Systemic Bacterial Infection Animal Models
- Systemic models of infection are described in the literature. The following conditions can be used to assay the compounds in this application. Bacteria are grown in Mueller-Hinton agar at 37° C. during 24 h. For each experiment, a bacterial suspension is prepared by inoculating 4-5 bacterial colonies onto Mueller-Hinton broth (MHB) and by incubating at 37° C. for 24 hours to yield approximately 109 CFU/ml. BalbC female mice are supplied by Charles River (Deutschland). Animals are infected by a single administration of an LD100 dose of bacterial culture suspension (1×108 CFU/100 μl per animal) in the tail vein. A careful clinical examination is made several times a day, and obvious clinical symptoms and mortality are recorded. Animals survival is observed for a period of 6 days. Azithromycin is dissolved in 0.5% methocel in saline solution and administered orally. Test compounds are micronized with mortar and pestle and then dissolved in methocel saline solution with 3% of DMF. The first dose is administered 30 minutes after infection, with following doses every 12 hours for 3 days.
- In vivo Efficacy Testing—S. aureus Mouse Septicaemia Model.
- Several compounds were tested in aS. aureus mouse protection models for efficacy. Two compounds, 25 and 62, protected 40% of treated animals from the lethal infection when administered orally.
- Clinical Uses of the Heterocyclic Compounds
- The compounds claimed in this invention can be used therapeutically or prophylactically for treatment or prevention of bacterial infections and/or diseases.
- The invention also relates to methods of disrupting the internal regulation of microbial growth or respiration, in a subject, comprising the step of administering to said subject a compound of any of the formulae described herein or a composition comprising a compound of any of the formulae described herein. In one embodiment, the invention relates to a method of inhibiting microbial or bacterial activity in a subject comprising the step of administering a compound to the subject, or a composition comprising a compound, of any one of the formulae described herein. Preferably, the subject is a human being or animal.
- In an alternate embodiment, this invention relates to a method of treating disease or disease symptoms in a subject comprising the step of administering to said subject a compound, or a composition comprising a compound, of any of the formulae described herein. Preferably, the subject is a human being or animal.
- Infections and infectious diseases are caused from a variety of microorganisms. The compounds of the invention may find use in the medical treatment of infectious diseases from bacterial sources.
- Compounds that kill or limit the growth of microorganisms may find use in the treatment of infections and infectious diseases. Specific bacterial microorganisms are known to be associated with the type of infection or infectious disease. Some examples of bacterial infections and their most common causative pathogens are given below.
- Upper and lower respiratory tract infections include, but are not limited to: bronchitis, sinusitis, pneumonia, sore throat, chronic streptococcal infections, diphtheria, acute epiglottitis, influenza, chronic bronchitis, middle ear infections (otitis media), pneumonia, bronchopneumonia, Legionnaire's disease, atypical pneumonia, whooping cough, and tuberculosis.
- Bacterial microorganisms causing respiratory tract infections include but are not limited to:S.pyogenes, S.pneumoniae, S.aureus, H.influenzae, M.catarrhalis, N.meningitidis, B. pertussis,, Enterobacteriaceae, Anerobes, Nocardia, Pseudomonas, C. psittaci, and C. diphtheriae.
- Urinary tract infections include, but are not limited to: urethritis, cystitis, pyelonephritis (kidney infection), asymptomatic bacteruria, interstitial cystitis, acute urethral syndrome, and recurrent urinary tract infections.
- Bacterial microorganisms causing urinary tract infections include but are not limited to:E. coli, Proteus, Providentia, Pseudomonas, Klebsiella, Enterobacter, Serratia, Coag. neg. Staphylococci, Enterococci, and C. trachomatis.
- Skin and wound infections include, but are not limited to: erythrasma, panaritium, impetigo, folliculitis, erysipelas, cellulitis, and necrotizing fasciitis.
- Bacterial microorganisms causing skin and wound infections include but are not limited to: Streptococci, Staphylococci,P. aeruginosa, P. acnes, Clostridia, anaerobes, and B. fragilis.
- Bacterial microorganisms causing systemic infections (bacteremia) include but are not limited to: Streptococci, Staphylococci, Enterobacteriaceae, Pseudomonas, Bacteroides sp., Neisseria,H. influenzae, Brucella, Listeria, and S. typhi.
- Sexually transmitted diseases of bacterial origin include, but are not limited to: adnexitis, cervicitis, chanchroid, urethritis, balanitis, gonorrhea, lymphogranuloma venereum, syphilis, and granuloma inguinale.
- Bacterial microorganisms causing sexually transmitted infections include but are not limited to: Chlamydia,N. gonorrhoeae, U. urealyticum, T. pallidium, G. vaginalis, H. ducreyi, C. granulomatis, Streptococci, Staphylococci, and Enterobacteriae.
- Gastrointestinal infections of bacterial origin include but are not limited to: food borne infections, colitis, enteritis, gastric ulcers, duodenal ulcers, pancreatitis, gall bladder infections, cholera, and thyphus.
- Bacterial microorganisms causing gastrointestinal infections include but are not limited to:H. pylori, C. pylori, C. duodeni, S. typhi, S. paratyphi, V. cholerae, anaerobes, Enterobacteriaceae, Staphylococci, and Streptococci.
- Methods of Treating Patients
- The heterocyclic compounds of the formulae delineated herein can be administered to a patient, for example, in order to treat an infection such as a bacterial infection. The heterocyclic compounds can, for example, be administered in a pharmaceutically acceptable carrier such as physiological saline, in combination with other drugs, and/or together with appropriate excipients. The heterocyclic compounds of the formulae described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.001 to about 100 mg/kg of body weight, preferably dosages between 10 mg and 5000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations contain from about 20% to about 80% active compound.
- Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.
- Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
- In another embodiment, this invention provides methods of treating, preventing, or relieving symptoms of disease in a subject comprising the step of administrating to said subject any of the pharmaceutical compositions and combinations described above. Preferably, the subject is a human. If the pharmaceutical composition only comprises the compound of this invention as the active component, such methods may additionally comprise the step of administering to said subject an additional therapeutic agent such as, for example, a sulfa drug or a sulfonamide (e.g., sulfamethoxzole), macrolide antibiotics (e.g., clarithromycin), proton pump inhibitors (e.g., omeprazole), rifamycins (e.g., rifampin), aminoglycosides (e.g., streptomycin, gentamycin,, tobramycin), penicillins (e.g., penicillin G, penicillin V, ticarcillin), β-lactamase inhibitors, cephalosporins (e.g., cefazolin, cefaclor, ceftazidime), and antimycobacterial agents (e.g., isoniazid, ethambutol). Other suitable agents are delineated in infectious disease texts and publications, including for example,Principles and Practice of Infectious Diseases, G. L. Mandell et al. eds., 3rd ed., Churchhill Livingstone, N.Y., (1990). Such additional(s) agent may be administered to the subject prior to, concurrently with, or following the administration of the composition having a compound of any of the formulae described herein.
- Pharmaceutical compositions of this invention comprise a compound of the formulae described herein or a pharmaceutically acceptable salt thereof; an additional agent selected from an anticancer agent, an anti-viral agent, antifungal agent, antibiotic, proton pump inhibitors, and any pharmaceutically acceptable carrier, adjuvant or vehicle. Alternate compositions of this invention comprise a compound of the formulae described herein or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, adjuvant or vehicle. Such compositions may optionally comprise additional therapeutic agents, including, for example an additional agent selected from an anticancer agent, an antiviral agent, antifungal agent, antibiotic, and any pharmaceutically acceptable carrier, adjuvant or vehicle. Alternate compositions of this invention comprise a compound of the formulae described herein or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, adjuvant or vehicle. Such compositions may optionally comprise additional therapeutic agents, including, for example an additional agent selected from an anticancer agent, an antimicrobial agent, an antiviral agent, antifungal agent, proton pump inhibitor, or antibiotic. The compositions delineated herein include the compounds of the formulae delineated herein, as well as additional therapeutic agents if present, in amounts effective for achieving a modulation of microbial or bacterial levels.
- The term “pharmaceutically acceptable carrier or adjuvant” refers to a carrier or adjuvant that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound.
- Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.
- The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the formulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
- The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens or Spans and/or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
- The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions and/or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying and/or suspending agents. If desired, certain sweetening and/or flavoring and/or coloring agents may be added.
- The pharmaceutical compositions of this invention may also be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
- Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application. For application topically to the skin, the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier with suitable emulsifying agents. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. The pharmaceutical compositions of this invention may also be topically applied to the lower intestinal tract by rectal suppository formulation or in a suitable enema formulation. Topically-transdermal patches are also included in this invention.
- The pharmaceutical compositions of this invention may be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other solubilizing or dispersing agents known in the art.
- The compounds and compositions of this invention are useful as sterilizants, antiseptics, adjuvants in wound dressings (e.g., bandages), and adjuvants in wound cleansing methods (swipes, gavage, etc.).
- When the compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen. The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
- Examples of potential application of combination therapies include compounds of any of the formulae delineated herein and the following: in combination with a macrolide antibiotic and a proton pump inhibitor for the treatment of gastritis and associated diseases caused byHelicobacter pylori; in combination with antibacterials (e.g., sulfamethoxazole, ciprofloxacin and amoxicillin) for the treatment of urinary tract infections; e.g. in combination with rifamycins for treatment of staphylococcal infections; e.g. in combination with rifamycins, isoniazid, ethambutol, or aminoglycosides for the treatment of mycobacterial infections; e.g. in combination with ticarcillin, gentamycin or tobramycin for the initial treatment of neutropenic patients with presumed infections, e.g. in combination with penicillins or aminoglycosides for the treatment of enterococcal endocarditis; e.g. in combination with antibiotics for the treatment of intraperitoneal, pelvic or other polymicrobial infections; e.g. in combination with other DHFR inhibitors (e.g., trimethoprim, DHFR inhibitors delineated herein).
- The invention will be further described in the following example. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.
- Liquid chromatographic data was obtained using a Hewlett-Packard (HP) 1090 Series Liquid Chromatograph coupled to a Diode Array Detector [Restek Allure C18 Column; particle size, 5 μM; column length, 150 mm; column diameter, 4.6 mm; flow rate, 1 mL/min; Solvent program, from 95% H2O (w/0.1% TFA)/5% CH3CN (w/0.1% TFA) to 100% CH3CN (w/0.1% TFA) in 8 minutes, then held constant for 3 minutes; detection wavelength, 254 nm]. Mass Spectral data were obtained on either an Agilent 1100 LC/MS or Thermofinigan AQA/Gilson LC/MS system. 1H- and 13C-NMR spectra were obtained on a Bruker AC-300 MHz instrument. Medium pressure flash chromatography was performed on an Isco Inc., Combiflash Sg100c system. Thin-layer chromatography was performed using EM Science silica gel 60 F254 plastic TLC plates. Melting points were determined in open-air capillary tubes in a Meltemp II apparatus. UV light was used for detecting compounds on the TLC plates. Reagents used in reactions were purchased from the Aldrich Chemical Co. (Milwaukee, Wis.), Sigma Chemical Co. (Saint Louis, Mo.), Fluka Chemical Corp. (Milwaukee, Wis.), Fisher Scientific (Pittsburgh, Pa.), TCI America (Portland, Oreg.), Transworld Chemicals, Inc. (Rockville, Md.), Maybridge Chemical Ltd., (London, England) or Lancaster Synthesis (Windham, N.H.).
-
-
- To a solution of 3,5-dichloroaniline (324 mg, 2 mmol) in dry DMF (5 mL) was added 2,4-diaminopteridine hydrochloride (100 mg, 0.4 mmol). The reaction vessel was flushed with dry nitrogen, sealed, and placed in an aluminum heating block at 85° C. for 3 days. The solvent was then rotary evaporated. Ethanol was added (2×15 mL) and rotary evaporated repeatedly. To the resulting crude product was added H2O (3 mL), HOAc (0.3 mL), and 1M HCl (0.1 mL) to pH˜2. The mixture was centrifuged to remove the insoluble impurities. The supernatant was removed and the pH adjusted to ˜5 with 1M NaOH (˜0.1 mL) to preciptate the product. This material was collected, washed with EtOH (3 mL), and dried under high vacuum to provide the purified product. HPLC rt 6.1 min, MS m/z.
- Nuclear magnetic resonance (NMR) spectroscopic analysis gave results consistent with the product.
-
- To a solution of 3-amino-4-methylbenzotrifluoride (3.35 g, 4.85 mmol) in DMF (10 mL) were added 2,4-diamino-6-chloromethylpteridine.HCl (1.57 g, 6.35 mmol) and K2CO3 (1.76 g, 12.7 mmol). The reaction mixture was purged with argon gas and heated to 60-65 C. for 24 hours in a sealed vial with vigorous strirring. The reaction mixture was then allowed to cool to room temperature and poured into 0.5N HCl (˜120 mL). The resulting mixture (pH 0-1; pH paper) was allowed to stir 15 minutes and then filtered. The collected precipitate was washed with 5% HCl, MeOH/CH2CL2, and Et2O. The product was dried under vacuum to provide the desired product (710 mg) as a yellow solid. This material was pure by RP-HPLC, Rt=3.25 min, m/z=350 (pos).
-
- To a solution of 4-chloro-1-naphthyl amine (3.70 g, 20.8 mmol) in DMF (10 mL) were added 2,4-diamino-6-chloromethylpteridine.HCl (1.58 g, 6.39 mmol) and K2CO3 (1.81 g, 13.0 mmol). The reaction mixture was purged with argon gas and heated to 60-65 C. for 34 hours in a sealed vial. The reaction mixture was then allowed to cool to room temperature and poured into excess 0.5N HCl. The pH of the resulting mixture was adjusted (NH4OH; pH 5; pH paper) and was then filtered. The collected precipitate was washed with 5H2O, MeOH/CH2CL2, and Et2O. The solid was suspended in Et2O and HCl (2N in Et2O, 6 mL) was added. The mixture was sealed and stirred for 0.5 hours. Evaporation, followed by drying under vacuum provided the product as a brown solid, which was ˜90% pure by HPLC and showed a significant amount of impurities.
- The brown solid was further purified by suspension in 0.5N HCl (120 mL) and conc. HCl (˜5 mL) was added in an attempt to dissolve the material. Despite the high acidity (pH<0, pH paper) a significant amount of material remained undissolved. The precipitate was collected and washed with H2O, MeOH/CH2Cl2, and Et2O. The product was dried to provide 1.33 grams of the desired product as a red solid which had high purity by HPLC, Rt=3.39 min; m/z=353 (pos).
-
- A mixture of 2.89 g (14.5 mmol) pyrimidine 11, 2.87 g (15 mmol) methylamine 1a and 2.5 ml (18 mmol) triethylamine in 25 mL of 2-methoxyethanol was stirred at 80° C. for 2 h. The reaction mixture was cooled down to room temperature and the solvent was evaporated to give a oily residue. 30 mL of ethyl acetate was added to dissolve the residue and the resulting solution was washed three times with water then dried over sodium sulfate. Evaporation gave an oily residue, which was then purified via the recrystallization from ether/hexane. 3.95 g of product 1b was obtained as white powder.
- To a solution of 3.71 g 1a in 40 mL of 2-methoxyethanol was added 24 mL of 1M guanidine in methanol and 16 mL of 1.5 M CH3ONa in CH3OH. The mixture was stirred at 140° C. for 12 h with an equipped Dean-Stark trap to remove the methanol solution. The reaction mixture was cooled down and evaporated in vacuo to give an oily residue, which was then dissolved in 30 mL of methanol. 50 mL of water was added to precipitate the product. The product was then purified by the recrystallization from methanol, then stirring in methanol three times. 920 mg of product was obtained as white powder. The purity of it was 98.52 % based on HPLC analysis.
-
- A similar procedures as for the preparation of compound 25 was used for the preparation of compound 62. 860 mg of final product was obtained as white powder, which had 98.80% of HPLC purity.
-
- Preparation of Compound 1:
- To a solution of 4.25 g (27.2 mmol) naphthaldehyde in 30 ml dry ether in ice water bath was slowly added 13 ml of ethylmagnesium bromide, 3 M in ether. The mixture was stirred for another 30 min at room temperature and then quenched by adding 40 ml of 1 N HCl solution. The organic layer was washed with water (20 ml), sat. sodium bicarbonate (20 ml×2), brine (20 ml) and then dried over anhydrous sodium sulfate. Evaporation of the organic solvent gave a crude product 1 which was directly used for the next step of the reaction without further purification
- Preparation of Compound 2:
- The crude product 1 was dissolved in 30 ml acetone and to the resulting mixture, bathed in an ice water bath, was slowly added Jone's reagent until the brown color persisted. The solution was further stirred for 15 min at room temperature and then 5 ml of isopropanol was added. After 50 ml of ethyl acetate was added, the resulting mixture was washed with water (30 ml), sat. sodium bicarbonate (30 ml×2), sat. NaCl and then dried over anhydrous sodium sulfate. Evaporation of the organic solvents gave an oily residue which was then purified by silica gel column chromatography. 4.01 g of ketone 2 was obtained.
- Preparation of Compound 3:
- To the mixture of 4.01 g ketone 2 and 16.3 ml of methylamine in methanol, 2 M, was added 1.61 g sodium cyanoborohydride and 160 mg of zinc chloride. The resulting mixture was stirred overnight at 50° C. Adding 1N HCl quenched the reaction. After most of the methanol was removed in vacuo, the solution was extracted with dichloromethane (15 ml×2). The pH of the aqueous layer was adjusted to about 9 with 2 N NaOH. The product was then extracted with dichloromethane (15 ml×3). The combined organic layer was washed with sat. NaCl and then dried over anhydrous sodium sulfate. Evaporation of the solvent gave 3.54 g of compound 3.
- Preparation of Compound 4:
- A mixture of 2.89 g (14.5 mmol) pyrimidine 11, 3.54 g (15 mmol) of compound 3 and 2.5 ml (18 mmol) triethylamine in 25 mL of 2-methoxyethanol was stirred at 80° C. for 2 h. The resulting mixture was cooled down to room temperature and the solvent was evaporated to give an oily residue. 30 mL of ethyl acetate was added to dissolve the residue and the resulting solution was washed three times with water then dried over anhydrous sodium sulfate. Evaporation gave an oily residue, which was then purified by silica gel column chromatography. 3.95 g of product 4 was obtained as white powder.
- Preparation of Compound 33:
- To a solution of 3.60 g of compound 4 in 40 mL of 2-methoxyethanol was added 24 mL of 1M guanidine in methanol and 16 mL of 1.5 M CH3ONa in CH3OH. The mixture was stirred at 140° C. for 12 h with an equipped Dean-Stark trap to remove the methanol solution. The reaction mixture was cooled down and evaporated in vacuo to give an oily residue, which was then dissolved in 30 mL of methanol. 50 mL of water was added to precipitate the product. The product was then purified by recrystallization from methanol, and the recrystallized product was then stirred in methanol three times. 1.95 g of the product was obtained as white powder. The purity of it was greater than 99% based on HPLC analysis.
- It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.
Claims (71)
1. A compound of the following formulae:
wherein
A is N, CH, or CR15;
R14 is —(CH2)n—X—Y, wherein
n is 1, 2, 3, 4, 5, or 6;
X is O, NH, or NR15; and
Y is aryl or heteroaryl, wherein each Y is optionally substituted with 1-4 independent R16;
each R15 is independently lower alkyl;
each R16 is independently halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, S(O)2NR17R17, S(O)2R17, C(O)OR18, C(O)NH2, or C(O)NR19R20;
each R17 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21;
each R18 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21;
each R19 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21;
each R20 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21; and
each R21 is independently hydrogen, alkyl, aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl, wherein each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, or heteroarylalkoxy.
2. The compound of claim 1 , wherein A is N.
3. The compound of claim 1 , wherein n is 1.
4. The compound of claim 1 , wherein Y is phenyl, optionally substituted with 1-4 independent R16.
5. The compound of claim 3 , wherein X is O.
6. The compound of claim 5 , wherein A is N.
7. The compound of claim 6 , wherein Y is phenyl, optionally substituted with 1-4 independent R16.
9. The compound of claim 8 , wherein each R16 is independently halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)OR18, C(O)NH2, or C(O)NR19R20.
11. The compound of claim 5 , wherein Y is phenyl, optionally substituted with 1-4 independent R16.
12. The compound of claim 11 , wherein phenyl is substituted with 1-4 independent R16.
13. The compound of claim 3 , wherein X is NH or NR15, and R15 is CH3.
14. The compound of claim 13 , wherein A is N.
15. The compound of claim 14 , wherein Y is phenyl, optionally substituted with 1-4 independent R16.
16. The compound of claim 15 , wherein Y is phenyl.
17. The compound of claim 15 , wherein each R16 is independently halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)OR18, C(O)NH2, or C(O)NR19R20.
19. The compound of claim 17 , wherein each R16 is C(O)OR18.
20. The compound of claim 19 , wherein each R18 is H or alkyl.
21. The compound of claim 20 , wherein each R18 is CH3.
22. The compound of claim 17 , wherein each R16 is C(O)NR19R20.
24. The compound of claim 14 , wherein Y is
optionally substituted with 1-4 independent R16, each R16 being halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)OR18, C(O)NH2, or C(O)NR19R20.
26. The compound of claim 13 , wherein Y is phenyl, optionally substituted with 1-4 independent R16.
27. The compound of claim 13 , wherein Y is
optionally substituted with 1-4 independent R16, each R16 being halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)OR18, C(O)NH2, or C(O)NR19R20.
28. The compound of claim 4 , wherein A is N.
29. The compound of claim 4 , wherein Y is phenyl, substituted with 1-4 independent R16.
30. The compound of claim 4 , wherein Y is phenyl.
33. The compound of claim 1 , wherein A is CH or CR15.
34. The compound of claim 1 , wherein each R16 is independently C(O)NR19R20.
35. The compound of claim 34 , wherein each R19 is independently aminoalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; and each R20 is independently aminoalkyl, aryl, or arylalkyl; each aryl or heteroaryl is optionally substituted with 1-4 independent halo, cyano, alkyl, trifluoromethyl, hydroxyalkyl, alkylenedioxo, aryl, heteroaryl, arylalkyl, heteroarylalkyl, nitro, hydroxy, mercapto, amino, alkoxy, thioalkoxy, trifluoromethoxy, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, C(O)R15, C(O)OR21, C(O)NR21R21, S(O)2NR21R21, or S(O)2R21.
36. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
37. A composition comprising a compound of claim 1 , an additional therapeutic agent, and a pharmaceutically acceptable carrier.
38. A composition comprising a compound of claim 1 , an additional therapeutic agent, and a pharmaceutically acceptable carrier, wherein the additional therapeutic agent is an antibacterial agent.
39. A method of for prophylaxis of bacterial infection and or treatment of a bacterially infected organism, comprising administering to the organism an effective amount of a compound of claim 1 .
40. A method for treating infection in a mammal comprising administration of the composition of claim 36 .
41. A method of making a compound of claim 1 , comprising taking a 2,4-diamino pteridinyl compound and reacting it with one or more chemical reagents in one or more steps to produce a compound of claim 1 .
42. A product made by the method of claim 41 .
43. A method of making a compound of claim 1 , comprising taking any one of the intermediate compounds described herein and reacting it with one or chemical reagents in one or more steps to produce a compound of claim 1 .
44. A product made by the method of claim 43 .
45. A method for identifying a compound having antibacterial activity, comprising:
a) assessing the structure of a compound of claim 1;
b) procuring a derivative compound of the compound from step a); and
c) assessing the antibacterial activity of the derivative compound.
46. A method for identifying a compound having antibacterial activity comprising:
a) taking a candidate compound of claim 1;
b) assessing the binding affinity of the candidate compound in a model of the hDHFR enzyme; and
c) assessing the antibacterial activity of the candidate compound.
47. A compound comprising the formula:
wherein
A and B are independently selected from the group consisting of N and CR7, wherein R7 is hydrogen or a carbon-, nitrogen-, sulfur- halogen- and/or oxygen-containing function group;
R1 and R2 are —NR5R6 groups, wherein R5 and R6 are independently hydrogen or carbon-containing functional groups;
R3 is hydrogen;
R4 is a carbon-, nitrogen-, sulfur-, halogen-, and/or oxygen-containing functional group,
provided that,
if A and B are both nitrogen and R5 and R6 are both hydrogen, then R4 is not —NH2, —N(H)(methyl), —N(H)(butyl), —N(H)(hexyl), —N(H)(phenyl), —N(H)(benzyl), —N(H)(NH2), —N(H)(CH2CH2OH), —N(CH2CH2OH)2, phenyl, N-piperidinyl, or —S(ethyl);
if A is CH, B is nitrogen, and R5 and R6 are both hydrogen, then R4 is not methyl, isobutyl, phenyl, 4-methylphenyl, 4-chlorophenyl, 4-bromophenyl, 2-(2,5-dimethoxyphenyl)-ethyl, or —CH(OCH3)2; and
if A and B are both CH groups, then R4 is an amino group other than —NH2, (3,4-dichlorophenyl)methylamino, or (3,4-dichlorophenyl)methyleneimino.
48. The compound of claim 47 wherein,
R5 and R6 are independently hydrogen; and
A and B are each independently N.
49. The compound of claim 48 wherein,
R4 is NR7R8;
R7 is C1-C6 alkyl substituted with aryl or heteroaryl;
R8 is C1-C6 alkyl optionally substituted with alkenyl, hydroxyl, alkoxy, cycloalkyl, or aryl.
50. The compound of claim 49 wherein,
R7 is C1-C6 alkyl substituted with aryl;
R8 is C1-C6 alkyl.
51. The compound of claim 49 wherein,
R7 is C1-C6 alkyl substituted with heteroaryl;
R8 is C1-C6 alkyl.
52. The compound of claim 49 wherein,
R7 is C1-C6 alkyl substituted with aryl;
R8 is C1-C6 alkyl substituted with hydroxyl or alkoxy.
53. The compound of claim 48 wherein,
R4 is NR7R8;
R7 is C1-C6 alkyl;
R8 is C1-C6 alkyl substituted with cycloalkyl.
54. The compound of claim 48 wherein,
R4 is NR7R8;
R7 is independently C1-C6 alkyl substituted with aryl;
R8 is independently C1-C6 alkyl substituted with aryl.
55. The compound of claim 48 , wherein
R7 is hydrogen, alkyl, cycloalkyl, aryl, halogen, thioalkyl, hydroxy, alkoxy, amino, alkyl, or NR5R6; wherein each R5 and R6 on the nitrogen atom independently is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, heteroarylalkyl, or alkylcarbonyl.
56. The compound of claim 50 , wherein R7 is C1-C6 alkyl substituted with naphthyl, which is optionally substituted with alkyl, halo, hydroxy, alkoxy, thioalkyl, or amino.
57. The compound of claim 56 , wherein the naphthyl group is substituted at the 2- or 4-position.
58. The compound of claim 57 , wherein R8 is methyl or ethyl.
59. The compound of claim 51 , wherein R7 is C1-C6 alkyl substituted with benzothienyl, which is optionally substituted with alkyl, halo, hydroxy, alkoxy, thioalkyl, or amino.
60. The compound of claim 59 , wherein R8 is methyl or ethyl.
61. A composition comprising a compound of claim 47 and a pharmaceutically acceptable carrier.
62. A composition comprising a compound of claim 47 , an additional therapeutic agent, and a pharmaceutically acceptable carrier.
63. A composition comprising a compound of claim 47 , an additional therapeutic agent, and a pharmaceutically acceptable carrier, wherein the additional therapeutic agent is an antibacterial agent.
64. A method of for prophylaxis of bacterial infection and or treatment of a bacterially infected organism, comprising administering to the organism an effective amount of a compound of claim 47 .
65. A method for treating infection in a mammal comprising administration of the composition of claim 61 .
66. A method of making a compound of claim 47 , comprising taking a 2,4-diamino pyrimidopyrimidinyl compound and reacting it with one or more chemical reagents in one or more steps to produce a compound of claim 47 .
67. A product made by the method of claim 66 .
68. A method of making a compound of claim 47 , comprising taking any one of the intermediate compounds described herein and reacting it with one or chemical reagents in one or more steps to produce a compound of claim 47 .
69. A product made by the method of claim 68 .
70. A method for identifying a compound having antibacterial activity, comprising:
a) assessing the structure of a compound of claim 47;
b) procuring a derivative compound of the compound from step a); and
c) assessing the antibacterial activity of the derivative compound.
71. A method for identifying a compound having antibacterial activity comprising:
a) taking a candidate compound of claim 47;
b) assessing the binding affinity of the candidate compound in a model of the hDHFR enzyme; and
c) assessing the antibacterial activity of the candidate compound.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/184,855 US20030176436A1 (en) | 2001-06-28 | 2002-06-28 | Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30168501P | 2001-06-28 | 2001-06-28 | |
US10/184,855 US20030176436A1 (en) | 2001-06-28 | 2002-06-28 | Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030176436A1 true US20030176436A1 (en) | 2003-09-18 |
Family
ID=23164426
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/185,059 Expired - Fee Related US7345048B2 (en) | 2001-06-28 | 2002-06-28 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors |
US10/184,855 Abandoned US20030176436A1 (en) | 2001-06-28 | 2002-06-28 | Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof |
US11/951,214 Abandoned US20080090847A1 (en) | 2001-06-28 | 2007-12-05 | Heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/185,059 Expired - Fee Related US7345048B2 (en) | 2001-06-28 | 2002-06-28 | Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/951,214 Abandoned US20080090847A1 (en) | 2001-06-28 | 2007-12-05 | Heterocyclic compounds and uses thereof as d-alanyl-d-alanine ligase inhibitors |
Country Status (16)
Country | Link |
---|---|
US (3) | US7345048B2 (en) |
EP (2) | EP1432713A4 (en) |
CN (2) | CN1547472A (en) |
BG (1) | BG108548A (en) |
BR (1) | BR0211310A (en) |
CA (2) | CA2451840A1 (en) |
CZ (2) | CZ200442A3 (en) |
EA (1) | EA200400094A1 (en) |
EE (2) | EE200400042A (en) |
HU (2) | HUP0700061A2 (en) |
IL (2) | IL159540A0 (en) |
MX (1) | MXPA04000159A (en) |
PL (2) | PL374589A1 (en) |
SK (1) | SK302004A3 (en) |
WO (2) | WO2003002064A2 (en) |
YU (2) | YU102503A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010107977A2 (en) * | 2009-03-20 | 2010-09-23 | Board Of Regents Of The University Of Texas System | Method for imparting antimicrobial activity to a medical device |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0217703D0 (en) * | 2002-07-31 | 2002-09-11 | Univ Liverpool | Pharmaceutical composition |
MX2007005408A (en) * | 2004-11-09 | 2007-05-16 | Hoffmann La Roche | Aminoquinazolines compounds. |
WO2007009911A1 (en) * | 2005-07-21 | 2007-01-25 | F. Hoffmann-La Roche Ag | PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS |
GB0608822D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of DHFR |
SI22338A (en) * | 2006-08-18 | 2008-02-29 | Univerza V Ljubljani, Fakulteta Za Farmacijo | Diazenedicarboxamides as inhibitors of d-alanyl-d-alanin ligase |
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
CN101084901B (en) * | 2007-06-22 | 2011-12-21 | 复旦大学 | Staphylococcus inhibitor |
CN101983191B (en) * | 2008-02-01 | 2013-11-20 | 武田药品工业株式会社 | Oxim derivatives as hsp90 inhibitors |
CA2769922A1 (en) * | 2009-08-31 | 2011-03-03 | Dow Agrosciences Llc | Pteridines and their use as agrochemicals |
ES2656225T3 (en) | 2015-03-04 | 2018-02-26 | Gilead Sciences, Inc. | Toll type receptor that modulates 4,6-diamino-pyrido [3,2-d] pyrimidine compounds |
CN106316966A (en) * | 2015-06-15 | 2017-01-11 | 董运勤 | Preparation method of medical intermediate N-(2-methylpyrazine)benzylamine phosphate compound |
WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
MA46093A (en) | 2016-09-02 | 2021-05-19 | Gilead Sciences Inc | TOLL-TYPE RECEIVER MODULATING COMPOUNDS |
MX390722B (en) | 2017-02-01 | 2025-03-21 | Univ Yale | DIURETIC RESISTANCE TREATMENT. |
SG11202006157VA (en) | 2018-01-05 | 2020-07-29 | Corvidia Therapeutics Inc | Methods for treating il-6 mediated inflammation without immunosuppression |
CA3127789A1 (en) * | 2019-02-01 | 2020-08-06 | Fmc Corporation | Diamino-substituted pyridines and pyrimidines as herbicides |
TWI751517B (en) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
TWI751516B (en) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
CN119371422A (en) | 2019-06-28 | 2025-01-28 | 吉利德科学公司 | Method for preparing Toll-like receptor modulator compounds |
GB2626567A (en) * | 2023-01-26 | 2024-07-31 | De Montfort Univ | Quinazoline derivatives for use as a medicament |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2949466A (en) * | 1958-03-04 | 1960-08-16 | Parke Davis & Co | Pyrimidine compounds and means of producing the same |
US3134778A (en) * | 1963-08-20 | 1964-05-26 | Smith Kline French Lab | 2,5,7-triamino-4-phenyl (or thienyl)-pyrimido[4,5-d]pyrimidines |
US4079056A (en) * | 1975-03-31 | 1978-03-14 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Method of making pteridine compounds |
US4256738A (en) * | 1977-11-10 | 1981-03-17 | Boehringer Ingelheim Gmbh | 9-(ω-Heteroarylamino-alkylamino)-erythromycins and salts thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RO56210A2 (en) | 1970-12-28 | 1974-08-01 | ||
DE3445298A1 (en) * | 1984-12-12 | 1986-06-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW PTERIDINE, METHOD FOR THE PRODUCTION AND USE THEREOF AS INTERMEDIATE PRODUCTS OR AS A MEDICINAL PRODUCT |
WO1992017478A1 (en) | 1991-04-08 | 1992-10-15 | Duquesne University Of The Holy Ghost | 5-ALKYL-6-[[AMINO]METHYL]PYRIDO[2,3-d]PYRIMIDINE DERIVATIVES AND METHODS OF PREPARING AND USING THESE DERIVATIVES |
US5547954A (en) * | 1994-05-26 | 1996-08-20 | Fmc Corporation | 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides |
ES2207657T3 (en) * | 1995-02-27 | 2004-06-01 | F. Hoffmann-La Roche Ag | PIRROLDERIVADOS DE DIOXOPIRROLO. |
WO1999050264A1 (en) | 1998-03-30 | 1999-10-07 | Kyowa Hakko Kogyo Co., Ltd. | Quinazoline derivatives |
JP2000239277A (en) | 1999-02-19 | 2000-09-05 | Kyowa Hakko Kogyo Co Ltd | Imidazoquinazoline derivative |
GB0219893D0 (en) | 2002-08-27 | 2002-10-02 | Melacure Therapeutics Ab | Pharmaceutically active compounds |
-
2002
- 2002-06-28 WO PCT/US2002/020479 patent/WO2003002064A2/en active Search and Examination
- 2002-06-28 CZ CZ200442A patent/CZ200442A3/en unknown
- 2002-06-28 HU HU0700061A patent/HUP0700061A2/en unknown
- 2002-06-28 US US10/185,059 patent/US7345048B2/en not_active Expired - Fee Related
- 2002-06-28 YU YU102503A patent/YU102503A/en unknown
- 2002-06-28 BR BRPI0211310-4A patent/BR0211310A/en not_active IP Right Cessation
- 2002-06-28 MX MXPA04000159A patent/MXPA04000159A/en not_active Application Discontinuation
- 2002-06-28 CA CA002451840A patent/CA2451840A1/en not_active Abandoned
- 2002-06-28 EP EP02753353A patent/EP1432713A4/en not_active Withdrawn
- 2002-06-28 IL IL15954002A patent/IL159540A0/en unknown
- 2002-06-28 EE EEP200400042A patent/EE200400042A/en unknown
- 2002-06-28 EE EEP200400043A patent/EE200400043A/en unknown
- 2002-06-28 PL PL02374589A patent/PL374589A1/en not_active Application Discontinuation
- 2002-06-28 CN CNA028166604A patent/CN1547472A/en active Pending
- 2002-06-28 CA CA002451800A patent/CA2451800A1/en not_active Abandoned
- 2002-06-28 CZ CZ200443A patent/CZ200443A3/en unknown
- 2002-06-28 EP EP02759101A patent/EP1411949A4/en not_active Withdrawn
- 2002-06-28 IL IL15953802A patent/IL159538A0/en unknown
- 2002-06-28 SK SK30-2004A patent/SK302004A3/en not_active Application Discontinuation
- 2002-06-28 YU YU102303A patent/YU102303A/en unknown
- 2002-06-28 PL PL02374259A patent/PL374259A1/en unknown
- 2002-06-28 US US10/184,855 patent/US20030176436A1/en not_active Abandoned
- 2002-06-28 WO PCT/US2002/020567 patent/WO2003001887A2/en not_active Application Discontinuation
- 2002-06-28 EA EA200400094A patent/EA200400094A1/en unknown
- 2002-06-28 HU HU0700040A patent/HUP0700040A2/en unknown
- 2002-06-28 CN CNA028150651A patent/CN1543465A/en active Pending
-
2004
- 2004-01-28 BG BG108548A patent/BG108548A/en unknown
-
2007
- 2007-12-05 US US11/951,214 patent/US20080090847A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2949466A (en) * | 1958-03-04 | 1960-08-16 | Parke Davis & Co | Pyrimidine compounds and means of producing the same |
US3134778A (en) * | 1963-08-20 | 1964-05-26 | Smith Kline French Lab | 2,5,7-triamino-4-phenyl (or thienyl)-pyrimido[4,5-d]pyrimidines |
US4079056A (en) * | 1975-03-31 | 1978-03-14 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Method of making pteridine compounds |
US4256738A (en) * | 1977-11-10 | 1981-03-17 | Boehringer Ingelheim Gmbh | 9-(ω-Heteroarylamino-alkylamino)-erythromycins and salts thereof |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010107977A2 (en) * | 2009-03-20 | 2010-09-23 | Board Of Regents Of The University Of Texas System | Method for imparting antimicrobial activity to a medical device |
WO2010107977A3 (en) * | 2009-03-20 | 2011-03-31 | Board Of Regents Of The University Of Texas System | Method for imparting antimicrobial activity to a medical device |
GB2480791A (en) * | 2009-03-20 | 2011-11-30 | Univ Texas | Method of imparting antimicrobial activity to a medical device |
US8426044B2 (en) | 2009-03-20 | 2013-04-23 | Board Of Regents, The University Of Texas System | Method for imparting antimicrobial activity to a medical device |
GB2480791B (en) * | 2009-03-20 | 2014-11-05 | Univ Texas | Method for imparting antimicrobial activity to a medical device |
Also Published As
Publication number | Publication date |
---|---|
CZ200442A3 (en) | 2004-10-13 |
CZ200443A3 (en) | 2004-08-18 |
PL374259A1 (en) | 2005-10-03 |
CN1543465A (en) | 2004-11-03 |
CN1547472A (en) | 2004-11-17 |
EP1432713A4 (en) | 2005-05-11 |
US20030181470A1 (en) | 2003-09-25 |
EP1432713A2 (en) | 2004-06-30 |
HUP0700061A2 (en) | 2007-05-02 |
BR0211310A (en) | 2006-10-31 |
WO2003001887A3 (en) | 2003-08-21 |
EP1411949A2 (en) | 2004-04-28 |
CA2451840A1 (en) | 2003-01-09 |
EE200400042A (en) | 2004-10-15 |
EE200400043A (en) | 2004-10-15 |
PL374589A1 (en) | 2005-10-31 |
IL159540A0 (en) | 2004-06-01 |
WO2003002064A3 (en) | 2003-10-23 |
US20080090847A1 (en) | 2008-04-17 |
US7345048B2 (en) | 2008-03-18 |
IL159538A0 (en) | 2004-06-01 |
YU102503A (en) | 2006-08-17 |
WO2003001887A2 (en) | 2003-01-09 |
EA200400094A1 (en) | 2005-08-25 |
HUP0700040A2 (en) | 2007-05-29 |
WO2003002064A2 (en) | 2003-01-09 |
MXPA04000159A (en) | 2005-01-07 |
YU102303A (en) | 2006-08-17 |
CA2451800A1 (en) | 2003-01-09 |
BG108548A (en) | 2005-05-31 |
EP1411949A4 (en) | 2004-11-24 |
SK302004A3 (en) | 2005-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030176436A1 (en) | Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof | |
JP4489586B2 (en) | 2-ureido-6-heteroaryl-3H-benzimidazole-4-carboxylic acid derivatives and related compounds as gyrase and / or topoisomerase IV inhibitors to treat bacterial infections | |
EP0009425B1 (en) | Novel naphtyridine derivatives and pharmaceutical compositions containing them | |
JP4691033B2 (en) | Gyrase inhibitor and use thereof | |
EP1963329B1 (en) | Inhibitors of c-met and uses thereof | |
JP2006528677A5 (en) | ||
CA2824403C (en) | Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea | |
KR20070048762A (en) | Zyrase Inhibitors and Uses thereof | |
EP2742044B1 (en) | Antibacterial homopiperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones | |
SG191924A1 (en) | Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea | |
CN118878557A (en) | A pan-KRAS inhibitor compound | |
US9879002B2 (en) | PDE10 inhibitors and related compositions and methods | |
KR20170139036A (en) | Heterocyclic-imidazole-based compounds, their drug compositions and their preparation and use | |
US9688659B2 (en) | Deuterated compounds for treating hematologic malignancies, and compositions and methods thereof | |
CN110662539B (en) | Methods of use of trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors | |
JPH0471076B2 (en) | ||
AU2002313649A1 (en) | Fused pyrimidine DHFR inhibitors as antibacterials | |
WO2003000255A1 (en) | Novel nitrofuran-containing heterocyclic compounds and uses thereof | |
KR102646627B1 (en) | Dual antagonist of adenosine A2A receptor and adenosine A2B receptor, and use thereof | |
KR102621694B1 (en) | Adenosine a2a receptor antagonist and use thereof | |
AU2002324455A1 (en) | Fused pyrimidines as d-alanyl-d-alanine ligase inhibitors | |
KR101893005B1 (en) | Novel luffariellolide pyridazinone derivatives and antibacterial composition comprising thereof | |
CZ20033474A3 (en) | Novel pyridylmethylaminopyrimidines | |
CN118359601A (en) | Aromatic acetylene derivative and preparation method and application thereof | |
NZ612912B2 (en) | Solid forms of gyrase inhibitor (r)-1-ethyl-3-[5-[2-{1-hydroxy-1-methyl-ethyl}pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl}-1h-benzimidazol-2-yl]urea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |